8,040 results on '"Extracorporeal membrane oxygenation"'
Search Results
152. Escalation from intra-aortic balloon pump to axillary impella 5.5 support: Staged removal of the femoral access.
- Author
-
Sosa, Carlos Vazquez, Ohira, Suguru, Ahmad, Hasan, Isath, Ameesh, De La Pena, Corazon, Spielvogel, David, and Kai, Masashi
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *INTRA-aortic balloon counterpulsation , *HEART assist devices , *CATHETERIZATION , *MEDICAL device removal , *RETROSPECTIVE studies , *HEART failure , *HEMATOMA , *TREATMENT effectiveness , *GROIN , *SURGICAL hemostasis , *COMPRESSION therapy , *DISEASE complications , *CASE studies , *FEMORAL artery , *FLUOROSCOPY - Abstract
Background: With the growing population of advanced heart failure, the use of Impella 5.5 has been increasing. Here, we report an effective strategy of removing the intra-aortic balloon pump (IABP) in the setting of escalation of support to Impella 5.5. Results: From January 1, 2022 to June 30, 2022, a total of 6 patients have undergone IABP removal during Impella 5.5 insertion. The IABP was subsequently removed over the long wire with manual compression on the femoral artery to control bleeding. An 8 or 9 Fr short sheath is inserted over the wire. Staged hemostasis was successfully performed in 4 patients, and the remaining two patients required escalation of support to veno-arterial membrane oxygenation as EC-PELLA utilizing the femoral arterial sheath. Conclusion: This does not only achieve secured hemostasis but also enables a smooth transition to further escalate support such as extracorporeal membrane oxygenation support, if necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
153. Massive post-infarction ventricular septal rupture complicaing cardiogenic shock with long term veno-arterial extracorporeal membrane oxygenation support.
- Author
-
Wang, Wei, Feng, Ying, Lin, Xin, Wu, Xiangyang, Chen, Gang, Ma, Ruchao, and Guan, Xinqiang
- Subjects
- *
ANTIBIOTICS , *CARDIOGENIC shock , *PHYSICAL diagnosis , *EXTRACORPOREAL membrane oxygenation , *SEVERITY of illness index , *TREATMENT effectiveness , *HEMODYNAMICS , *ULTRASONIC imaging , *VENTRICULAR septal rupture , *DISEASE complications ,MYOCARDIAL infarction diagnosis - Abstract
Introduction: Ventricular septal rupture (VSR) following acute myocardial infarction (AMI) is a rare but serious complication often causing cardiogenic shock (CS). The timing of surgery is a difficult problem for surgeons because of high mortality and surgical complexity. We present a case of successful use of extracorporeal membrane oxygenation (ECMO) for maintaining haemodynamic stability preoperative and delaying surgical repair of VSR patient in severe CS. Case report: A 57-year-old man with AMI complicated by severe CS due to an massive VSR. Emergency surgery was considered a too high mortality risk. The patient was implanted with a percutaneous veno-arterial ECMO (VA-ECMO) system as a bridge to surgery for stabilizing general condition. On the 31th day after ECMO implantation, the ventricular septal defect was successfully repaired and weaning from the ECMO. Discussion: This case study illustrates that it may be considered to use long term ECMO preoperative to delayed surgery which leads to higher survival in cases of massive VSR patient after AMI in hemodynamically compromised patients. Still the optimal duration of mechanical circulatory support and the optimal timing for surgery need more research to define. Conclusion: This case indicates the feasibility of preoperative using of a long term VA-ECMO as a bridge to surgical repair of VSR patient after AMI in severe CS. The optimal duration of mechanical circulatory support and the optimal timing for surgery still require further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
154. Patient‐tailored platelet transfusion practices for children supported by extracorporeal membrane oxygenation.
- Author
-
Schiller, Ofer, Pula, Giulia, Shostak, Eran, Manor‐Shulman, Orit, Frenkel, Georgy, Amir, Gabriel, Yacobovich, Joanne, Nellis, Marianne E., and Dagan, Ovadia
- Subjects
- *
BLOOD platelet transfusion , *EXTRACORPOREAL membrane oxygenation , *RED blood cell transfusion , *CHILD support , *CHILD patients , *PLATELET count - Abstract
Background and Objectives: Extracorporeal membrane oxygenation (ECMO) serves as cardiopulmonary therapy in critically ill patients with respiratory/heart failure and often necessitates multiple blood product transfusions. The administration of platelet transfusions during ECMO is triggered by the presence or risk of significant bleeding. Most paediatric ECMO programmes follow guidelines that recommend a platelet transfusion threshold of 80–100 × 109/L. To reduce exposure to platelets, we developed a practice to dynamically lower the threshold to ~20 × 109/L. We describe our experience with patient‐tailored platelet thresholds and related bleeding outcomes. Materials and Methods: We retrospectively evaluated our platelet transfusion policy, bleeding complications and patient outcome in 229 ECMO‐supported paediatric patients in our unit. Results: We found that more than 97.4% of patients had a platelet count <100 × 109/L at some point during their ECMO course. Platelets were transfused only on 28.5% of ECMO days; and 19.2% of patients never required a platelet transfusion. The median lowest platelet count in children who had bleeding events was 25 × 109/L as compared to 33 × 109/L in children who did not bleed (p < 0.001). Our patients received fewer platelet transfusions and did not require more red blood cell transfusions, nor did they experience more haemorrhagic complications. Conclusion: We have shown that a restrictive, 'patient‐tailored' rather than 'goal‐directed' platelet transfusion policy is feasible and safe, which can greatly reduce the use of platelet products. Although there was a difference in the lowest platelet counts in children who bled versus those who did not, the median counts were much lower than current recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
155. Nursing Care of a Child With Delirium Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Case Report.
- Author
-
Fu, Cong-hui, Li, Yan, Zhang, Yu-cai, Yang, Xiao-ya, Liu, Ji, Ju, Min-jie, and Xu, Ting-ting
- Subjects
- *
RISK assessment , *CONTINUING education units , *NURSES , *EXTRACORPOREAL membrane oxygenation , *CARDIOMYOPATHIES , *OCCUPATIONAL roles , *NURSING , *FAMILY roles , *PEDIATRICS , *ANALGESIA , *DELIRIUM , *INTENSIVE care units , *SHOCK (Pathology) , *VENTRICULAR arrhythmia , *SLEEP , *VOMITING , *MEDICAL screening , *ANESTHESIA , *CRITICAL care nurses , *CHILDREN - Abstract
Introduction: Children receiving extracorporeal membrane oxygenation are prone to delirium. This case report describes the nursing care of a child with delirium who received venoarterial extracorporeal membrane oxygenation. Relevant interventions and precautions are also discussed. Clinical Findings: A 6-year-old girl was admitted to the pediatric intensive care unit with a 2-day history of vomiting and fever. The child underwent cannulation for venoarterial extracorporeal membrane oxygenation. Diagnosis: The child was diagnosed with acute fulminant myocarditis, cardiac shock, and ventricular arrhythmia. Interventions: On the third day of extracorporeal membrane oxygenation, bedside nurses began using the Cornell Assessment of Pediatric Delirium to assess the child for delirium symptoms. The team of physicians and nurses incorporated a nonpharmacologic delirium management bundle into pediatric daily care. Delirium screening, analgesia and sedation management, sleep promotion, and family participation were implemented. Outcomes: During the 18 days of pediatric intensive care unit hospitalization, the child had 6 days of delirium: 1.5 days of hypoactive delirium, 1.5 days of hyperactive delirium, and 3 days of mixed delirium. The child was successfully discharged home on hospital day 22. Conclusion: Caring for a child with delirium receiving venoarterial extracorporeal membrane oxygenation required multidimensional nursing capabilities to prevent and reduce delirium while ensuring safe extracorporeal membrane oxygenation. This report may assist critical care nurses caring for children under similar circumstances. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
156. Empowering Little Fighters: Post-Cardiotomy Pediatric ECMO and the Journey to Recovery.
- Author
-
Kumar, Alok, Raj, Sangeeth, Singh, Saurabh, Ghotra, Gurpinder S., and Tiwari, Nikhil
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *SURGICAL complications , *CARDIOPULMONARY bypass , *CONGENITAL heart disease , *PULMONARY arterial hypertension , *ARRHYTHMIA , *BLOOD lactate - Abstract
Introduction: Extra Corporeal Membrane Oxygenation (ECMO) has long been used for cardiorespiratory support in the immediate postpaediatric cardiac surgery period with a 2-3% success as per the ELSO registry. Success in recovery depends upon the optimal delivery of critical care to paediatric patients and a comprehensive healthcare team. Methodology: The survival benefit of children placed on central veno arterial (VA) ECMO following elective cardiac surgeries for congenital heart disease (n = 672) was studied in a cohort of 29 (4.3%) cases from the period of Jan 2018 to Dec 2022 in our cardiac surgical centre. Indications for placing these patients on central VA ECMO included inability to wean from cardiopulmonary bypass (CPB), low cardiac output syndrome, severe pulmonary arterial hypertension, significant bleeding, anaphylaxis, respiratory failure and severe pulmonary edema. Results: The mean time to initiation of ECMO was less than 5 h and the mean duration of ECMO support was 56 h with a survival rate of 58.3%. Amongst perioperative complications, sepsis and arrhythmia on ECMO were found to be negatively associated with survival. Improvements in the pH, PaO2 levels and serum lactate levels after initiation of ECMO were associated with survival benefits. Conclusion: The early initiation of ECMO for paediatric cardiotomies could be a beacon of hope for families and medical teams confronting these challenging situations. Improvement in indicators of adequate perfusion and ventricular recoveries like pH and serum lactate and absence of arrhythmia and sepsis are associated with good outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
157. Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation.
- Author
-
Kido, Kazuhiko, Kabulski, Galen M., Szymanski, Thomas W., Shiga, Tsuyoshi, Shimizu, Mikiko, and Hashiguchi, Masayuki
- Subjects
- *
BIVALIRUDIN , *META-analysis , *CONFIDENCE intervals , *EXTRACORPOREAL membrane oxygenation , *THROMBOEMBOLISM , *DESCRIPTIVE statistics , *HEPARIN , *ODDS ratio , *ADULTS - Abstract
Introduction: Unfractionated heparin (UFH) has traditionally been the agent of choice in patients on extracorporeal membrane oxygenation (ECMO). However, direct thrombin inhibitors (DTI) have recently garnered more attention in ECMO because of their advantages over UFH. Given the heterogeneous results of multiple recent published studies, we performed a meta-analysis to describe pooled outcomes between bivalirudin and UFH anticoagulation in patients on ECMO. Methods: Relevant studies were identified from MEDLINE and Google Scholar database searches through April 23, 2022. The primary efficacy outcome was thromboembolism (TE), and secondary efficacy outcomes included all-cause mortality and circuit thrombosis. The primary safety outcome was major bleeding. Results: A total of 6 studies were included in the meta-analysis. Bivalirudin use was associated with significantly lower risk of TE (OR 0.61; 95% CI 0.38-.99; P =.05; I 2 = 0%) and circuit thrombosis (OR 0.51; 95% CI.32-.80; P =.004; I 2 = 0%) compared with UFH. There was no significant difference in all-cause mortality risk (OR 0.75; 95% CI.52−1.09; P =.13; I 2 = 30%) between the bivalirudin and UFH groups. No significant difference in the risk of major bleeding between 2 groups was found (OR 0.67; 95% CI 0.25−1.81; P =.43; I 2 = 80%). Conclusion: These data support that bivalirudin is a reasonable alternative to UFH in patients on ECMO. Randomized controlled trials are needed to confirm bivalirudin's efficacy and safety results compared with UFH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
158. Hemolysis Index Correlations with Plasma-Free Hemoglobin and Plasma Lactate Dehydrogenase in Critically Ill Patients under Extracorporeal Membrane Oxygenation or Mechanical Circulatory Support—A Single-Center Study.
- Author
-
Zapletal, Bernhard, Zimpfer, Daniel, Schlöglhofer, Thomas, Fritzer-Szekeres, Monika, Szekeres, Thomas, Bernardi, Martin H., Geilen, Johannes, Schultz, Marcus J., and Tschernko, Edda M.
- Subjects
- *
ARTIFICIAL blood circulation , *BLOOD lactate , *EXTRACORPOREAL membrane oxygenation , *LACTATE dehydrogenase , *CRITICALLY ill - Abstract
Monitoring for thrombosis and hemolysis is crucial for patients under extracorporeal or mechanical circulatory support, but it can be costly. We investigated correlations between hemolysis index (HI) and plasma-free hemoglobin (PFH) levels on one hand, and between the HI and plasma lactate dehydrogenase (LDH) levels on the other, in critically ill patients with and without extracorporeal or mechanical circulatory support. Additionally, we calculated the cost reductions if monitoring through HI were to replace monitoring through PFH or plasma LDH. In a single-center study, HI was compared with PFH and plasma LDH levels in blood samples taken for routine purposes in critically ill patients with and without extracorporeal or mechanical circulatory support. A cost analysis, restricted to direct costs associated with each measurement, was made for an average 10-bed ICU. This study included 147 patients: 56 patients with extracorporeal or mechanical circulatory support (450 measurements) and 91 patients without extracorporeal or mechanical circulatory support (562 measurements). The HI correlated well with PFH levels (r = 0.96; p < 0.01) and poorly with plasma LDH levels (r = 0.07; p < 0.01) in patients with extracorporeal or mechanical circulatory support. Similarly, HI correlated well with PFH levels (r = 0.97; p < 0.01) and poorly with plasma LDH levels (r = −0.04; p = 0.39) in patients without extracorporeal or mechanical circulatory support. ROC analyses demonstrated a strong performance of HI, with the curve indicating excellent discrimination in the whole cohort (area under the ROC of 0.969) as well as in patients under ECMO or mechanical circulatory support (area under the ROC of 0.988). Although the negative predictive value of HI for predicting PFH levels > 10 mg/dL was high, its positive predictive value was found to be poor at various cutoffs. A simple cost analysis showed substantial cost reduction if HI were to replace PFH or plasma LDH for hemolysis monitoring. In conclusion, in this cohort of critically ill patients with and without extracorporeal or mechanical circulatory support, HI correlated well with PFH levels, but poorly with plasma LDH levels. Given the high correlation and substantial cost reductions, a strategy utilizing HI may be preferable for monitoring for hemolysis compared to monitoring strategies based on PFH or plasma LDH. The PPV of HI, however, is unacceptably low to be used as a diagnostic test. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
159. The CDH Study Group: Past, Present, and Future.
- Author
-
Holden, Kylie I., Ebanks, Ashley H., Lally, Kevin P., and Harting, Matthew T.
- Subjects
- *
MEDICAL personnel , *DIAPHRAGMATIC hernia , *CONSORTIA , *EXTRACORPOREAL membrane oxygenation - Abstract
The Congenital Diaphragmatic Hernia Study Group (CDHSG) is an international consortium of medical centers actively collecting and voluntarily contributing data pertaining to live born congenital diaphragmatic hernia (CDH) patients born and/or managed at their institutions. These data are aggregated to construct a comprehensive registry that participating centers can access to address specific clinical inquiries and track patient outcomes. Since its establishment in 1995, 147 centers have taken part in this initiative, including 53 centers from 17 countries outside the United States, with 95 current active centers across the globe. The registry has amassed data on over 14,000 children, resulting in the creation of over 75 manuscripts based on registry data to date. International, multicenter consortia enable health care professionals managing uncommon, complex, and diverse diseases to formulate evidence-based hypotheses and draw meaningful and generalizable conclusions for clinical inquiries. This review will explore the formation and structure of the CDHSG and its registry, outlining their functions, center participation, and the evolution of data collection. Additionally, we will provide an overview of the evidence generated by the CDHSG, with a particular emphasis on contributions post-2014, and look ahead to the future directions the study group will take in addressing CDH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
160. Influence of Covid-19 disease on hemostasis dynamics during extracorporeal membrane oxygenation (ECMO)1.
- Author
-
Rother, D., Gehron, J., Brenck, F., Hudel, H., Böning, A., and Wenzel, F.
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *COVID-19 , *ADULT respiratory distress syndrome , *HEMOSTASIS , *RIFAXIMIN - Abstract
INTRODUCTION: COVID-19 causes a considerable degradation of pulmonary function to the point of an acute respiratory distress syndrome (ARDS). Over the course of the disease the gas exchange capability of the lung can get impaired to such an extent that extracorporeal membrane oxygenation (ECMO) is needed as a life-saving intervention. In patients COVID-19 as well as ECMO may cause severe coagulopathies which manifest themselves in micro and macro thrombosis. Previous studies established D-dimers as a marker for critical thrombosis of the ECMO system while on admission increased D-dimers are associated with a higher mortality in COIVD-19 patients. It is therefore crucial to determine if COVID-19 poses an increased risk of early thrombosis of the vital ECMO system. METHODS: 40 patients who required ECMO support were enrolled in a retrospective analysis and assigned into 2 groups. The COVID group consist of 20 COVID-19 patients who required ECMO support (n = 20), whereas 20 ECMO patients without COVID-19 were assigned to the control group. D-dimers, fibrinogen, antithrombin III (AT III), lactate dehydrogenase (LDH) and platelet count were analysed using locally weighted scatterplot smoothing and MANOVAs. RESULTS: The analysis of both groups shows highly significant differences in the dynamics of hemostasis. The increase in D-dimers that is associated with thrombosis of the ECMO systems occurs in COVID-19 patients around 2 days earlier (p = 2,8115 10–11) while fibrinogen is consumed steadily. In the control group fibrinogen levels increase rapidly after ten days with a plateau phase of around five days (p = 1,407 10–3) . Both groups experience a rapid increase in AT III after start of support by ECMO (p = 5,96 10–15). In the COVID group platelet count decreased from 210 giga/l to 130 giga/l within eight days, while in the same time span in the control group platelets decreased from 180 giga/l to 105 giga/l (p = 1,1 10–15). In both groups a marked increase in LDH beyond 5000 U/l occurs (p = 3,0865 10–15). CONCLUSION: The early increase in D-dimers and decrease in fibrinogen suggests that COVID-19 patients bear an increased risk of early thrombosis of the ECMO system compared to other diseases treated with ECMO. Additionally, the control group shows signs of severe inflammation 10 days after the start of ECMO which were absent in COVID-19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
161. Penetrating firearm tracheal injury with cardiac arrest due to tension pneumopericardium.
- Author
-
Patel, Takshaka, Dulak, Deirdre, Sjoholm, Lars Ola, and Petrov, Roman
- Subjects
- *
TRACHEA injuries , *TRACHEAL surgery , *EXTRACORPOREAL membrane oxygenation , *COMPUTED tomography , *THORACIC surgery , *CHEST X rays , *FIREARMS , *HEMODYNAMICS , *GUNSHOT wounds , *PNEUMOPERICARDIUM , *BRONCHOSCOPY , *HYPOXEMIA - Abstract
Firearm-associated tracheal injuries occur infrequently and as such there is no standard approach. We present a case of tension pneumopericardium due to a firearm-associated tracheal injury which was successfully repaired through an anterior midline sternotomy approach. In hemodynamically unstable patients who cannot tolerate posterolateral approaches, the anterior midline sternotomy approach to the airway should be considered. We demonstrate that this approach can provide adequate access for decompression of tension physiology and repair of airway injury. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
162. Safety, Surge, and Strain: Where and When Does Risk Occur in Critical Care?
- Author
-
Hick, John L. and Kadri, Sameer S.
- Subjects
- *
ENTERAL feeding , *EXTRACORPOREAL membrane oxygenation , *CRITICAL care medicine , *ADVANCED cardiac life support , *APACHE (Disease classification system) , *CRITICALLY ill patient care - Abstract
The article discusses the impact of the COVID-19 pandemic on critical care and the relationship between surge conditions and mortality. A study conducted in the Netherlands found that as COVID-19 hospitalizations increased, the number of patients in the ICU with non-COVID conditions decreased. There was also a small but clear relationship between surge conditions and mortality, indicating the strain on healthcare resources and its impact on patient safety. The study highlights the need to consider the risks of deferred surgeries and the quality of care provided during high caseloads. ICUs worldwide are facing strain due to capacity and staffing issues, which has highlighted the risk of mortality. However, there is limited understanding of the factors that impact patient outcomes. There is a need for better data and research definitions to define ICU care beyond just location. Using markers of patient acuity and interventions such as pressors and mechanical ventilation can help assess the risk. It is important to capture changes in staffing and training levels. Data lakes with patient data could be used to identify safety risks, but they are often not coupled with temporal data or hospital information. Healthcare should follow the aviation industry's example and agree to submit essential information to a third party to shape our understanding of the relationship between strain and safety. At the bedside, proactive evaluation of risk mitigation can be done through tests of change, such as new staffing models and smart technology. A surge index could be developed to predict and compare strain across hospitals. ICU care should focus on preventing adverse outcomes associated with infections and pressure [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
163. Oxygenation During Venoarterial Extracorporeal Membrane Oxygenation: Physiology, Current Evidence, and a Pragmatic Approach to Oxygen Titration.
- Author
-
Premraj, Lavienraj, Brown, Alastair, Fraser, John F., Pellegrino, Vincent, Pilcher, David, and Burrell, Aidan
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *OXYGEN in the blood , *OXYGEN saturation , *CLINICAL trials , *VOLUMETRIC analysis - Abstract
OBJECTIVES: This review aims to: 1) identify the key circuit and patient factors affecting systemic oxygenation, 2) summarize the literature reporting the association between hyperoxia and patient outcomes, and 3) provide a pragmatic approach to oxygen titration, in patients undergoing peripheral venoarterial extracorporeal membrane oxygenation (ECMO). DATA SOURCES: Searches were performed using PubMed, SCOPUS, Medline, and Google Scholar. STUDY SELECTION: All observational and interventional studies investigating the association between hyperoxia, and clinical outcomes were included, as well as guidelines from the Extracorporeal Life Support Organization. DATA EXTRACTION: Data from relevant literature was extracted, summarized, and integrated into a concise narrative review. For ease of reference a summary of relevant studies was also produced. DATA SYNTHESIS: The extracorporeal circuit and the native cardiorespiratory circuit both contribute to systemic oxygenation during venoarterial ECMO. The ECMO circuit's contribution to systemic oxygenation is, in practice, largely determined by the ECMO blood flow, whereas the native component of systemic oxygenation derives from native cardiac output and residual respiratory function. Interactions between ECMO outflow and native cardiac output (as in differential hypoxia), the presence of respiratory support, and physiologic parameters affecting blood oxygen carriage also modulate overall oxygen exposure during venoarterial ECMO. Physiologically those requiring venoarterial ECMO are prone to hyperoxia. Hyperoxia has a variety of definitions, most commonly Pa o2 greater than 150 mm Hg. Severe hypoxia (Pa o2 > 300 mm Hg) is common, seen in 20%. Early severe hyperoxia, as well as cumulative hyperoxia exposure was associated with in-hospital mortality, even after adjustment for disease severity in both venoarterial ECMO and extracorporeal cardiopulmonary resuscitation. A pragmatic approach to oxygenation during peripheral venoarterial ECMO involves targeting a right radial oxygen saturation target of 94-98%, and in selected patients, titration of the fraction of oxygen in the mixture via the air-oxygen blender to target postoxygenator Pa o2 of 150-300 mm Hg. CONCLUSIONS: Hyperoxia results from a range of ECMO circuit and patient-related factors. It is common during peripheral venoarterial ECMO, and its presence is associated with poor outcome. A pragmatic approach that avoids hyperoxia, while also preventing hypoxia has been described for patients receiving peripheral venoarterial ECMO. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
164. Outcomes of Extracorporeal Cardiopulmonary Resuscitation for In-Hospital Cardiac Arrest Among Children With Noncardiac Illness Categories.
- Author
-
Loaec, Morgann, Himebauch, Adam S., Reeder, Ron, Alvey, Jessica S., Race, Jonathan A., Lillian Su, Lasa, Javier J., Slovis, Julia C., Raymond, Tia T., Coleman, Ryan, Barney, Bradley J., Kilbaugh, Todd J., Topjian, Alexis A., Sutton, Robert M., and Morgan, Ryan W.
- Subjects
- *
CARDIOPULMONARY resuscitation , *CARDIAC resuscitation , *CARDIAC arrest , *CHILD patients , *BAYESIAN analysis - Abstract
OBJECTIVES: The objective of this study was to determine the association of the use of extracorporeal cardiopulmonary resuscitation (ECPR) with survival to hospital discharge in pediatric patients with a noncardiac illness category. A secondary objective was to report on trends in ECPR usage in this population for 20 years. DESIGN: Retrospective multicenter cohort study. SETTING: Hospitals contributing data to the American Heart Association's Get With The Guidelines-Resuscitation registry between 2000 and 2021. PATIENTS: Children (<18 yr) with noncardiac illness category who received greater than or equal to 30 minutes of cardiopulmonary resuscitation (CPR) for in-hospital cardiac arrest. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Propensity score weighting balanced ECPR and conventional CPR (CCPR) groups on hospital and patient characteristics. Multivariable logistic regression incorporating these scores tested the association of ECPR with survival to discharge. A Bayesian logistic regression model estimated the probability of a positive effect from ECPR. A secondary analysis explored temporal trends in ECPR utilization. Of 875 patients, 159 received ECPR and 716 received CCPR. The median age was 1.0 [interquartile range: 0.2-7.0] year. Most patients (597/875; 68%) had a primary diagnosis of respiratory insufficiency. Median CPR duration was 45 [35-63] minutes. ECPR use increased over time (p < 0.001). We did not identify differences in survival to discharge between the ECPR group (21.4%) and the CCPR group (16.2%) in univariable analysis (p = 0.13) or propensity-weighted multivariable logistic regression (adjusted odds ratio 1.42 [95% CI, 0.84-2.40; p = 0.19]). The Bayesian model estimated an 85.1% posterior probability of a positive effect of ECPR on survival to discharge. CONCLUSIONS: ECPR usage increased substantially for the last 20 years. We failed to identify a significant association between ECPR and survival to hospital discharge, although a post hoc Bayesian analysis suggested a survival benefit (85% posterior probability). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
165. Higher Survival With the Use of Extracorporeal Cardiopulmonary Resuscitation Compared With Conventional Cardiopulmonary Resuscitation in Children Following Cardiac Surgery: Results of an Analysis of the Get With The Guidelines-Resuscitation Registry.
- Author
-
Kobayashi, Ryan L., Gauvreau, Kimberlee, Alexander, Peta M. A., Teele, Sarah A., Fynn-Thompson, Francis, Lasa, Javier J., Bembea, Melania, and Thiagarajan, Ravi R.
- Subjects
- *
CARDIAC surgery , *CARDIOPULMONARY resuscitation , *EXTRACORPOREAL membrane oxygenation , *CARDIAC arrest , *PROPENSITY score matching - Abstract
OBJECTIVES: Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation (CPR) is increasingly used in children suffering cardiac arrest after cardiac surgery. However, its efficacy in promoting survival has not been evaluated. We compared survival of pediatric cardiac surgery patients suffering in-hospital cardiac arrest who were resuscitated with extracorporeal CPR (E-CPR) to those resuscitated with conventional CPR (C-CPR) using propensity matching. DESIGN: Retrospective study using multicenter data from the American Heart Association Get With The Guidelines-Resuscitation registry (2008-2020). SETTING: Multicenter cardiac arrest database containing cardiac arrest and CPR data from U.S. hospitals. PATIENTS: Cardiac surgical patients younger than 18 years old who suffered in-hospital cardiac arrest and received greater than or equal to 10 minutes of CPR. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Among 1223 patients, 741 (60.6%) received C-CPR and 482 (39.4%) received E-CPR. E-CPR utilization increased over the study period (p < 0.001). Duration of CPR was longer in E-CPR compared with C-CPR recipients (42 vs. 26 min; p < 0.001). In a propensity score matched cohort (382 E-CPR recipients, 382 C-CPR recipients), E-CPR recipients had survival to discharge (odds ratio [OR], 2.22; 95% CI, 1.7-2.9; p < 0.001). E-CPR survival was only higher when CPR duration was greater than 18 minutes. Propensity matched analysis using patients from institutions contributing at least one E-CPR case (n = 35 centers; 353 E-CPR recipients, 353 C-CPR recipients) similarly demonstrated improved survival in E-CPR recipients compared with those who received C-CPR alone (OR, 2.08; 95% CI, 1.6-2.8; p < 0.001). CONCLUSIONS: E-CPR compared with C-CPR improved survival in children suffering cardiac arrest after cardiac surgery requiring CPR greater than or equal to 10 minutes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
166. Prognostic Significance of Signs of Life in Out-of-Hospital Cardiac Arrest Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation.
- Author
-
Naofumi Bunya, Hirofumi Ohnishi, Takehiko Kasai, Yoichi Katayama, Ryuichiro Kakizaki, Satoshi Nara, Shinichi Ijuin, Akihiko Inoue, Toru Hifumi, Tetsuya Sakamoto, Yasuhiro Kuroda, and Eichi Narimatsu
- Subjects
- *
CARDIAC arrest , *CARDIOPULMONARY resuscitation , *CARDIAC patients , *BYSTANDER CPR , *TREATMENT effectiveness , *VENTRICULAR fibrillation - Abstract
OBJECTIVES: Signs of life (SOLs) during cardiac arrest (gasping, pupillary light reaction, or any form of body movement) are suggested to be associated with favorable neurologic outcomes in out-of-hospital cardiac arrest (OHCA). While data has demonstrated that extracorporeal cardiopulmonary resuscitation (ECPR) can improve outcomes in cases of refractory cardiac arrest, it is expected that other contributing factors lead to positive outcomes. This study aimed to investigate whether SOL on arrival is associated with neurologic outcomes in patients with OHCA who have undergone ECPR. DESIGN: Retrospective multicenter registry study. SETTING: Thirty-six facilities participating in the Study of Advanced life support for Ventricular fibrillation with Extracorporeal circulation in Japan II (SAVE-J II). PATIENTS: Consecutive patients older than 18 years old who were admitted to the Emergency Department with OHCA between January 1, 2013, and December 31, 2018, and received ECPR. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patients were classified into two groups according to the presence or absence of SOL on arrival. The primary outcome was a favorable neurologic outcome (Cerebral Performance Category 1 or 2) at discharge. Of the 2157 patients registered in the SAVE-J II database, 1395 met the inclusion criteria, and 250 (17.9%) had SOL upon arrival. Patients with SOL had more favorable neurologic outcomes than those without SOL (38.0% vs. 8.1%; p < 0.001). Multivariate analysis showed that SOL on arrival was independently associated with favorable neurologic outcomes (odds ratio, 5.65 [95% CI, 3.97-8.03]; p < 0.001). CONCLUSIONS: SOL on arrival was associated with favorable neurologic outcomes in patients with OHCA undergoing ECPR. In patients considered for ECPR, the presence of SOL on arrival can assist the decision to perform ECPR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
167. Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study.
- Author
-
Mayerhöfer, Timo, Joannidis, Michael, Peer, Andreas, Perschinka, Fabian, Fries, Dietmar, Mair, Peter, Gasteiger, Lukas, Bachler, Mirjam, Kilo, Juliane, Herkner, Harald, Schwameis, Michael, Schellongowski, Peter, Nagler, Bernhard, Kornfehl, Andrea, Staudinger, Thomas, and Buchtele, Nina
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *ADULT respiratory distress syndrome , *ANTICOAGULANTS , *ANTITHROMBINS , *PARTIAL thromboplastin time , *COHORT analysis - Abstract
Direct thrombin inhibitors, including argatroban, are increasingly used for anticoagulation during venovenous extracorporeal membrane oxygenation (VV ECMO). In many centers activated partial thromboplastin time (aPTT) is used for monitoring, but it can be affected by several confounders. The aim of this study was to evaluate the safety and efficacy of anticoagulation with argatroban titrated according to diluted thrombin time targets (hemoclot™ assay) compared to anti-Xa guided anticoagulation with unfractionated heparin (UFH). This cohort study included adults at two tertiary care centers who required VV ECMO for severe COVID-19-related acute respiratory distress syndrome (CARDS). Patients received center-dependent argatroban or UFH for anticoagulation during ECMO. Argatroban was guided following a hemoclot™ target range of 0.4–0.6 μg/ml. UFH was guided by anti-factor Xa (antiXa) levels (0.2–0.3 IU/ml). The primary outcome was safety of argatroban compared to UFH, assessed by time to first clinically relevant bleeding event or death during ECMO. Secondary outcomes included efficacy (time to thromboembolism) and feasibility (proportion of anticoagulation targets within range). From 2019 to 2021 57 patients were included in the study with 27 patients (47 %) receiving argatroban and 30 patients (53 %) receiving UFH. The time to the first clinically relevant bleeding or death during ECMO was similar between groups (HR (argatroban vs. UFH): 1.012, 95 % CI 0.44–2.35, p = 0.978). Argatroban was associated with a decreased risk for thromboembolism compared to UFH (HR 0.494 (95 % CI 0.26–0.95; p = 0.034)). The overall proportion of anticoagulation within target ranges was not different between groups (46 % (23–54 %) vs. 46 % (37 %–57 %), p = 0.45). Anticoagulation with argatroban according to hemoclot™ targets (0.4–0.6 μg/ml) compared to antiXa guided UFH (0.2–0.3 IU/ml) is safe and may prolong thromboembolism-free time in patients with severe ARDS requiring VV ECMO. [Display omitted] • Time to first clinically relevant bleeding was similar in patients treated with argatroban and unfractionated heparin • Argatroban was associated with a reduced risk of thromboembolism compared to unfractionated heparin • The overall proportion of anticoagulation within target ranges did not differ between groups [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
168. Influence of cardiac diagnosis on outcomes of pediatric heart‐lung transplantation.
- Author
-
Sainathan, Sandeep, Ryan, John, Mullinari, Leonardo, and Sanchez, Pablo
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *TREATMENT effectiveness , *CONGENITAL heart disease , *DIAGNOSIS , *HEART diseases , *KIDNEY transplantation , *HEART assist devices , *PULMONARY hypertension - Abstract
Objective: Pediatric Heart‐lung transplant (HLTX) is performed for endstage congenital heart disease (CHD) with irreversible pulmonary hypertension or non‐congenital heart disease (NCHD) with end‐stage heart and lung disease. CHD could influence the outcomes of HTLX due to increased complexity of the operation as compared to NCHD. In this study we evaluated the influence of cardiac diagnosis on outcomes of pediatric HTLX. Methods: The UNOS database (1987–2022) was queried for primary HTLX in patients <18 years. The data were extracted for demographics, pretransplant characteristics, post‐transplant outcomes, and analyzed for the impact of cardiac diagnosis on post‐transplant outcomes. Standard statistical tests were used. Survival was compared using the Kaplan–Meier method. Results: Ninety of the 213 patients who underwent HLTX had CHD. There were no demographic differences. Heart listing status was similar but with a higher LAS score for NCHD. NCHD had higher pre‐operative life support use (mechanical ventilation, inotropes or dialysis) but the use of ECMO as a bridge to transplantation was similar. Wait‐list times were longer for CHD. The ischemic times were similar. Post‐transplant dialysis, stroke, prolonged mechanical ventilation, and rejection were similar. Survival at 30‐days, 1‐year, and long‐term survival at 17 years was similar. Non‐survivors at 30‐days post‐transplant were on life support, used ECMO as a bridge, had lower wait‐list times, longer ischemic times and had strokes. Non‐survivors at 1‐year had similar factors in addition to a higher dialysis use. Conclusion: Cardiac diagnosis had no impact on outcomes after Pediatric HLTX. Patients on life support or ECMO before transplantation were transplanted faster but with lower survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
169. Effectiveness of HA330 hemoperfusion as an adjunctive therapy for severe COVID-19 patients: a single center experience.
- Author
-
Phongphithakchai, Atthaphong, Saelue, Pirun, Wongpraphairot, Suwikran, and Boonsrirat, Ussanee
- Subjects
- *
COVID-19 , *HEMOPERFUSION , *COVID-19 treatment , *CYTOKINE release syndrome , *PARTIAL pressure - Abstract
Background & objective: Cytokine storms play a significant role in conditions leading to multi-organ failure in patients with severe corona virus disease-2019 (COVID-19). The eradication of pro-inflammatory cytokines through hemoperfusion has been suggested to be a possible strategy to improve outcomes in these patients. We evaluated the impact of adjunctive HA330 hemoperfusion on outcomes in severe COVID-19 patients. Methodology: A single-center retrospective cohort study was conducted from December 2021 to December 2022. We included severe COVID-19 patients with elevated pro-inflammatory markers, who received three consecutive sessions of HA330 hemoperfusion in addition to the standard treatment protocol. Clinical data, including demographic information, baseline characteristics, and treatment outcomes, were analyzed. Results: We evaluated 24 severe COVID-19 patients. We observed a significant reduction in levels of CRP (P < 0.001) and IL-6 (P = 0.042), as well as a significant increase in arterial partial pressure of oxygen (P = 0.041). Importantly, no patient experienced cytotoxicity after the HA330 hemoperfusion sessions, confirming the biocompatibility of the treatment. Conclusion: Three consecutive sessions of HA330 hemoperfusion, used as an adjunctive therapy to standard care in severe COVID-19 patients, effectively reduced pro-inflammatory cytokine levels and improved oxygenation. However, large multicenter trials are required to validate these clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
170. Association between body composition and mortality in patients requiring extracorporeal membrane oxygenation support.
- Author
-
Takenoshita, M., Weir McCall, J.R., Barker, A.P., Suresh, S., Celik, H., and Vuylsteke, A.
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *ADULT respiratory distress syndrome , *PSOAS muscles , *BODY composition , *ABDOMINAL muscles , *SURVIVAL rate , *MUSCLE mass - Abstract
To ascertain the association between body composition, including muscle mass and adiposity, and patient mortality in those requiring extracorporeal membrane oxygenation (ECMO) for acute respiratory failure. A retrospective study was undertaken of all patients with acute respiratory failure requiring veno-venous (VV) ECMO between January 2015 and December 2019. Automated image segmentation software was used to quantify the cross-sectional area and average radiodensity (in Hounsfield units) of different muscle and fat compartments at the L3 level of whole-body computed tomography (CT) images taken within 48 h of initiation of ECMO support. The primary endpoint was 30-day post-ECMO initiation all-cause mortality. Logistic regression was used to analyse the correlation between CT measurements, co-morbidities, and 30-day survival. The study included 189 patients (age = 43.8 ± 14.6, sex = 42.3% female). There was no significant association between 30-day survival status and cross-sectional area of muscle or fat. Muscle attenuation (psoas, long spine, and abdominal muscles respectively) at the L3 level were significantly lower in those who died within 30 days of ECMO cannulation (p <0.05). On multivariable analysis including age, sex, and pre-existing respiratory comorbidities, psoas muscle attenuation was an independent predictor of survival at 30 days (OR 0.97; 95% CI 0.94 to 1.00; p =0.047). Reduced psoas muscle attenuation is associated with poorer survival outcomes at 30 days post-ECMO cannulation in patients who received VV ECMO support for respiratory failure. Cross-sectional areas of muscle and fat compartments did not correlate with survival outcomes at 30 days even when corrected for height and sex. • Neither muscle nor fat volumes were associated with outcomes. • Muscle attenuation was lower in those who died within 30 days of ECMO cannulation. • Psoas muscle attenuation was an independent predictor of survival at 30 days. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
171. Total Thyroidectomy while on Extracorporeal Membrane Oxygenation for Thyroid Storm.
- Author
-
Wee, Jia Jia, Tay, Kai Jun, Sudirman, Siti Radhziah Binte, and Loh, Shaun Ray Han
- Subjects
- *
THYROID crisis , *EXTRACORPOREAL membrane oxygenation , *THYROIDECTOMY , *HEART failure , *MULTIPLE organ failure , *HYPERTHYROIDISM - Abstract
Thyroid storm is an acute life-threatening condition of hyperthyroidism that can present with cardiac failure, requiring extracorporeal membrane oxygenation (ECMO). We present the first case reported of total thyroidectomy successfully performed while on ECMO for thyroid storm in a 32-year-old male. This case highlights the challenges of managing refractory thyroid storm with multi-organ failure. We demonstrate that total thyroidectomy may still be safely performed while on ECMO for thyroid storm, if steps are taken to optimise the patient perioperatively, with careful surgical and anaesthesia planning. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
172. Impact of Extracorporeal Membrane Oxygenation Circuitry on Remdesivir.
- Author
-
Cies, Jeffrey J., Moore II, Wayne S., Deacon, Jillian, Enache, Adela, and Chopra, Arun
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *REMDESIVIR , *OXYGENATORS , *CIRCUIT complexity - Abstract
OBJECTIVES This study aimed to determine the oxygenator impact on alterations of remdesivir (RDV) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extracorporeal membrane oxygenation (ECMO) circuit including the Quadrox-i oxygenator. METHODS One-quarter--inch and a 3/8-inch, simulated closed-loop ECMO circuits were prepared with a Quadrox-i pediatric and Quadrox-i adult oxygenator and blood primed. Additionally, 1/4-inch and 3/8-inch circuits were also prepared without an oxygenator in series. A 1-time dose of RDV was administered into the circuits and serial preoxygenator and postoxygenator concentrations were obtained at 0 to 5 minutes, and 1-, 2-, 3-, 4-, 5-, 6-, 8-, 12-, and 24-hour time points. The RDV was also maintained in a glass vial and samples were taken from the vial at the same time periods for control purposes to assess for spontaneous drug degradation. RESULTS For the 1/4-inch circuits with an oxygenator, there was a 35% to 60% RDV loss during the study period. For the 1/4-inch circuits without an oxygenator, there was a 5% to 20% RDV loss during the study period. For the 3/8-inch circuit with and without an oxygenator, there was a 60% to 70% RDV loss during the study period. CONCLUSIONS There was RDV loss within the circuit during the study period and the RDV loss was more pronounced with the larger 3/8-inch circuit when compared with the 1/4-inch circuit. The impact of the oxygenator on RDV loss appears to be variable and possibly dependent on the size of the circuit and oxygenator. These preliminary data suggest RDV dosing may need to be adjusted for concern of drug loss via the ECMO circuit. Additional single- and multiple-dose studies are needed to validate these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
173. Comparison of bleeding and thrombotic outcomes in veno‐venous extracorporeal membrane oxygenation: Heparin versus bivalirudin.
- Author
-
Kartika, Thomas, Mathews, Rick, Migneco, Gina, Bundy, Taylor, Kaempf, Andy J., Pfeffer, Michael, DeLoughery, Thomas G., Moore, Kerry, Beardshear, Rachel, Oetken, Heath J., Case, Jonathan, Hinds, Monica T., McCarty, Owen J. T., Shatzel, Joseph J., Zonies, David, and Zakhary, Bishoy
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *BIVALIRUDIN , *HEPARIN , *RED blood cell transfusion , *BLOOD platelets - Abstract
Objectives: We aimed to evaluate thrombotic and hemorrhagic complications with heparin versus bivalirudin use in veno‐venous extracorporeal membrane oxygenation (V‐V ECMO). Methods: We performed a retrospective cohort study of adult patients placed on V‐V ECMO with intravenous anticoagulation with either heparin or bivalirudin. Time to thrombotic event and major bleed were analyzed in addition to related outcomes. Results: We identified 95 patients placed on V‐V ECMO: 61 receiving heparin, 34 bivalirudin. The bivalirudin group had a higher rate of severe COVID‐19, higher BMI, and longer ECMO duration. Despite this, bivalirudin was associated with reduced risk of thrombotic event (HR 0.14, 95% CI 0.06–0.32, p <.001) and increased average lifespan of the circuit membrane lung (16 vs. 10 days, p = 0.004). While there was no difference in major bleeding, the bivalirudin group required fewer transfusions of packed red blood cells and platelets per 100 ECMO days (means of 13 vs. 39, p = 0.004; 5 vs. 19, p =.014, respectively). Lastly, the bivalirudin group had improved survival to ECMO decannulation in univariate analysis (median OS 53 vs. 26 days, p =.015). Conclusions: In this real‐world analysis of bivalirudin versus heparin, bivalirudin is a viable option for V‐V ECMO and associated with lower risk of thrombotic complications and fewer transfusion requirements. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
174. Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry.
- Author
-
Moayedifar, Roxana, Shudo, Yasuhiro, Kawabori, Masashi, Silvestry, Scott, Schroder, Jacob, Meyer, Dan M., Jacobs, Jeffrey P., D'Alessandro, David, and Zuckermann, Andreas
- Subjects
- *
HEART assist devices , *ARTIFICIAL blood circulation , *EXTRACORPOREAL membrane oxygenation , *HEART transplantation , *HEART failure patients , *HEART - Abstract
The prevalence of end-stage heart failure and patients who could benefit from heart transplantation requires an expansion of the donor pool, relying on the transplant community to continually re-evaluate and expand the use of extended criteria donor organs. Introduction of new technologies such as the Paragonix SherpaPak Cardiac Transport System aids in this shift. We seek to analyze the impact of the SherpaPak system on recipient outcomes who receive extended criteria organs in the GUARDIAN-Heart Registry. Between October 2015 and December 2022, 1,113 adults from 15 US centers receiving donor hearts utilizing either SherpaPak (n = 560) or conventional ice storage (ice, n = 453) were analyzed from the GUARDIAN-Heart Registry using summary statistics. A previously published set of criteria was used to identify extended criteria donors, which included 193 SherpaPak and 137 ice. There were a few baseline differences among recipients in the 2 cohorts; most notably, IMPACT scores, distance traveled, and total ischemic time were significantly greater in SherpaPak, and significantly more donor hearts in the SherpaPak cohort had >4 hours total ischemia time. Posttransplant mechanical circulatory support utilization (SherpaPak 22.3% vs ice 35.0%, p = 0.012) and new extracorporeal membrane oxygenation/ventricular assist device (SherpaPak 7.8% vs ice 15.3%, p = 0.033) was significantly reduced, and the rate of severe primary graft dysfunction (SherpaPak 6.2% vs ice 13.9%, p = 0.022) was significantly reduced by over 50% in hearts preserved using SherpaPak. One-year survival between cohorts was similar (SherpaPak 92.9% vs ice 89.6%, p = 0.27). This subgroup analysis demonstrates that SherpaPak can be safely used to utilize extended criteria donors with low severe PGD rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
175. Outcome after extracorporeal membrane oxygenation therapy in Norwood patients before the bidirectional Glenn operation.
- Author
-
Seeber, Fabian, Krenner, Niklas, Sames-Dolzer, Eva, Tulzer, Andreas, Srivastava, Ishita, Kreuzer, Michaela, Mair, Roland, Gierlinger, Gregor, Nawrozi, Mohammad-Paimann, and Mair, Rudolf
- Subjects
- *
CARDIAC surgery , *EXTRACORPOREAL membrane oxygenation , *MULTIVARIABLE testing , *EXTRACORPOREAL shock wave therapy , *HOSPITAL admission & discharge , *FACTOR analysis ,MORTALITY risk factors - Abstract
OBJECTIVES Patients after the Norwood procedure are prone to postoperative instability. Extracorporeal membrane oxygenation (ECMO) can help to overcome short-term organ failure. This retrospective single-centre study examines ECMO weaning, hospital discharge and long-term survival after ECMO therapy between Norwood and bidirectional Glenn palliation as well as risk factors for mortality. METHODS In our institution, over 450 Norwood procedures have been performed. Since the introduction of ECMO therapy, 306 Norwood operations took place between 2007 and 2022, involving ECMO in 59 cases before bidirectional Glenn. In 48.3% of cases, ECMO was initiated intraoperatively post-Norwood. Patient outcomes were tracked and mortality risk factors were analysed using uni- and multivariable testing. RESULTS ECMO therapy after Norwood (median duration: 5 days; range 0–17 days) saw 31.0% installed under CPR. Weaning was achieved in 46 children (78.0%), with 55.9% discharged home after a median of 45 (36–66) days. Late death occurred in 3 patients after 27, 234 and 1541 days. Currently, 30 children are in a median 4.8 year (3.4–7.7) follow-up. At the time of inquiry, 1 patient awaits bidirectional Glenn, 6 are at stage II palliation, Fontan was completed in 22 and 1 was lost to follow-up post-Norwood. Risk factor analysis revealed dialysis (P < 0.001), cerebral lesions (P = 0.026), longer ECMO duration (P = 0.002), cardiac indication and lower body weight (P = 0.038) as mortality-increasing factors. The 10-year mortality probability after ECMO therapy was 48.5% (95% CI 36.5–62.9%). CONCLUSIONS ECMO therapy in critically ill patients after the Norwood operation may significantly improve survival of a patient cohort otherwise forfeited and give the opportunity for successful future-stage operations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
176. Early outcomes after post-cardiotomy extracorporeal membrane oxygenation in paediatric patients: a contemporary, binational cohort study.
- Author
-
Crawford, Lachlan, Marathe, Supreet P, Betts, Kim S, Karl, Tom R, Mattke, Adrian, Rahiman, Sarfaraz, Campbell, Isobella, Inoue, Takamichi, Nair, Harikrishnan, Iyengar, Ajay, Konstantinov, Igor E, Collaborative, ANZCORS, Venugopal, Prem, and Alphonso, Nelson
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *CHILD patients , *HYPOPLASTIC left heart syndrome , *COHORT analysis , *PEDIATRIC surgery , *HOSPITAL mortality - Abstract
Open in new tab Download slide OBJECTIVES The aim of this study was to assess the early outcomes and risk factors of paediatric patients requiring extracorporeal membrane oxygenation after cardiac surgery (post-cardiotomy). METHODS Retrospective binational cohort study from the Australia and New Zealand Congenital Outcomes Registry for Surgery database. All patients younger than 18 years of age who underwent a paediatric cardiac surgical procedure from 1 January 2013 to 31 December 2021 and required post-cardiotomy extracorporeal membrane oxygenation (PC-ECMO) in the same hospital admission were included in the study. RESULTS Of the 12 290 patients included in the study, 376 patients required post-cardiotomy ECMO (3%). Amongst these patients, hospital mortality was 35.6% and two-thirds of patients experienced a major complication. Hypoplastic left heart syndrome was the most common diagnosis (17%). The Norwood procedure and modified Blalock–Taussig shunts had the highest incidence of requiring PC-ECMO (odds ratio of 10 and 6.8 respectively). Predictors of hospital mortality after PC-ECMO included single-ventricle physiology, intracranial haemorrhage and chylothorax. CONCLUSIONS In the current era, one-third of patients who required PC-ECMO after paediatric cardiac surgery in Australia and New Zealand did not survive to hospital discharge. The Norwood procedure and isolated modified Blalock–Taussig shunt had the highest incidence of requiring PC-ECMO. Patients undergoing the Norwood procedure had the highest mortality (48%). Two-thirds of patients on PC-ECMO developed a major complication. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
177. Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring.
- Author
-
Mikulska, Malgorzata, Melchio, Monica, Signori, Alessio, Ullah, Nadir, Miletich, Franca, Sepulcri, Chiara, Limongelli, Alessandro, Giacobbe, Daniele Roberto, Balletto, Elisa, Russo, Chiara, Magnasco, Laura, Vena, Antonio, Grazia, Carmen Di, Raiola, Anna Maria, Portunato, Federica, Dentone, Chiara, Battaglini, Denise, Ball, Lorenzo, Robba, Chiara, and Angelucci, Emanuele
- Subjects
- *
DRUG monitoring , *CRITICALLY ill , *EXTRACORPOREAL membrane oxygenation , *RENAL replacement therapy , *ASSISTED suicide - Abstract
Background Isavuconazole is first-line treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) is deemed not necessary, since most patients reached therapeutic levels (>1 mg/L) in large studies. Low levels were reported in some critically ill patients admitted to the ICU. The aim was to compare isavuconazole levels between critically ill and non-critically ill patients. Materials and methods Retrospective analysis of data from all patients treated with standard-dose isavuconazole between 1 January 2019 and 26 October 2022 was performed. The following data were collected: TDM results from the first 30 days of therapy; ward of admission; demographic and clinical characteristics; continuous renal replacement therapy; extracorporeal membrane oxygenation; and co-administered drugs. Results Seventy-two patients (median age 65 years) and 188 TDM measurements (mean number of samples per patient 2.6 ± 1.7) were included; 33 (45.8%) were ICU patients (3 also had haematological disorders); 39 (54.2%) were non-ICU patients, of whom 31 had haematological disorders. In all patients, the mean isavuconazole blood level was 3.33 ± 2.26 mg/L. Significantly lower levels were observed in the ICU versus the non-ICU population: mean 2.02 ± 1.22 versus 4.15 ± 2.31 mg/L (P < 0.001). Significantly higher rates of subtherapeutic levels were observed in ICU patients compared with the non-ICU population: all determinations <2 mg/L in 33.3% versus 7.7%, and all determinations <1 mg/L in 12.1% versus 0%, respectively. Predictors of lower isavuconazole levels were admission to the ICU, BMI > 25 kg/m2, bilirubin > 1.2 mg/dL and the absence of haematological disorder. Conclusions ICU patients had significantly lower isavuconazole blood levels compared to non-ICU population. The TDM of isavuconazole for efficacy should be performed in ICU. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
178. Extracorporeal membrane oxygenation in obstetric patients: An Israeli nationwide study.
- Author
-
Yahav‐Shafir, Dana, Ilgiyaev, Eduard, Galante, Ori, Gorfil, Dan, Statlender, Liran, Soroksky, Arie, Carmi, Uri, Sinai, Yitzhak Brzezinski, Iprach, Nisim, Haviv‐Yadid, Yael, Makhoul, Maged, Fatnic, Elena, Ginosar, Yehuda, Einav, Sharon, Helviz, Yigal, Fink, Daniel, Sternik, Leonid, and Kogan, Alexander
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *COVID-19 , *PERINATAL period , *PULMONARY hypertension , *CRITICAL care medicine , *AMNIOTIC fluid embolism , *ARACHNOID cysts - Abstract
Background: The leading causes of maternal mortality include respiratory failure, cardiovascular events, infections, and hemorrhages. The use of extracorporeal membrane oxygenation (ECMO) as rescue therapy in the peripartum period for cardiopulmonary failure is expanding in critical care medicine. Methods: This retrospective observational study was conducted on a nationwide cohort in Israel. During the 3‐year period, between September 1, 2019, and August 31, 2022, all women in the peripartum period who had been supported by ECMO for respiratory or circulatory failure at 10 large Israeli hospitals were identified. Indications for ECMO, maternal and neonatal outcomes, details of ECMO support, and complications were collected. Results: During the 3‐year study period, in Israel, there were 540 234 live births, and 28 obstetric patients were supported by ECMO, with an incidence of 5.2 cases per 100 000 or 1 case per 19 000 births (when excluding patients with COVID‐19, the incidence will be 2.5 cases per 100 000 births). Of these, 25 were during the postpartum period, of which 16 (64%) were connected in the PPD1, and 3 were during pregnancy. Eighteen patients (64.3%) were supported by V‐V ECMO, 9 (32.1%) by V‐A ECMO, and one (3.6%) by a VV‐A configuration. Hypoxic respiratory failure (ARDS) was the most common indication for ECMO, observed in 21 patients (75%). COVID‐19 was the cause of ARDS in 15 (53.7%) patients. The indications for the V‐A configuration were cardiomyopathy (3 patients), amniotic fluid embolism (2 patients), sepsis, and pulmonary hypertension. The maternal and fetal survival rates were 89.3% (n = 25) and 100% (n = 28). The average ECMO duration was 17.6 ± 18.6 days and the ICU stay was 29.8 ± 23.8 days. Major bleeding complications requiring surgical intervention were observed in one patient. Conclusions: The incidence of using ECMO in the peripartum period is low. The maternal and neonatal survival rates in patients treated with ECMO are high. These results show that ECMO remains an important treatment option for obstetric patients with respiratory and/or cardiopulmonary failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
179. Use of point-of-care ultrasound (POCUS) to monitor neonatal and pediatric extracorporeal life support.
- Author
-
Bianzina, Stefania, Singh, Yogen, Iacobelli, Roberta, Amodeo, Antonio, Guner, Yigit, and Di Nardo, Matteo
- Subjects
- *
MECONIUM aspiration syndrome , *EXTRACORPOREAL membrane oxygenation , *HIGH-frequency ventilation (Therapy) , *MEDICAL technology management , *ULTRASONIC imaging , *OXYGENATORS - Abstract
Extracorporeal membrane oxygenation (ECMO) is an invasive life support technique that requires a blood pump, an artificial membrane lung, and vascular cannulae to drain de-oxygenated blood, remove carbon dioxide, oxygenate, and return it to the patient. ECMO is generally used to provide advanced and prolonged cardiopulmonary support in patients with refractory acute cardiac and/or respiratory failure. After its first use in 1975 to manage a severe form of meconium aspiration syndrome with resultant pulmonary hypertension, the following years were dominated by the use of ECMO to manage neonatal respiratory failure and limited to a few centers across the world. In the 1990s, evidence for neonatal respiratory ECMO support increased; however, the number of cases began to decline with the use of newer pharmacologic therapies (e.g., inhaled nitric oxide, exogenous surfactant, and high-frequency oscillatory ventilation). On the contrary, pediatric ECMO sustained steady growth. Combined advances in ECMO technology and bedside medical management have improved general outcomes, although ECMO-related complications remain challenging. Point-of-care ultrasound (POCUS) is an essential tool to monitor all phases of neonatal and pediatric ECMO: evaluation of ECMO candidacy, ultrasound-guided ECMO cannulation, daily evaluation of heart and lung function and brain perfusion, detection and management of major complications, and weaning from ECMO support. Conclusion: Based on these considerations and on the lack of specific guidelines for the use of POCUS in the neonatal and pediatric ECMO setting, the aim of this paper is to provide a systematic overview for the application of POCUS during ECMO support in these populations. What is Known: • Extracorporeal membrane oxygenation (ECMO) provides advanced cardiopulmonary support for patients with refractory acute cardiac and/or respiratory failure and requires appropriate monitoring. • Point-of-care ultrasound (POCUS) is an accessible and adaptable tool to assess neonatal and pediatric cardiac and/or respiratory failure at bedside. What is New: • In this review, we discussed the use of POCUS to monitor and manage at bedside neonatal and pediatric patients supported with ECMO. • We explored the potential use of POCUS during all phases of ECMO support: pre-ECMO assessment, ECMO candidacy evaluation, daily evaluation of heart, lung and brain function, detection and troubleshooting of major complications, and weaning from ECMO support. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
180. Serial daily lactate levels association with 30-day outcome in cardiogenic shock patients treated with VA-ECMO: a post-hoc analysis of the HYPO-ECMO study.
- Author
-
Levy, Bruno, Girerd, Nicolas, Baudry, Guillaume, Duarte, Kevin, Cuau, Samuel, Bakker, Jan, and Kimmoun, Antoine
- Subjects
- *
CARDIOGENIC shock , *HYPOTHERMIA , *EXTRACORPOREAL membrane oxygenation , *CRITICALLY ill , *PATIENTS , *DATA analysis , *RESEARCH funding , *KRUSKAL-Wallis Test , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *CAUSES of death , *MANN Whitney U Test , *CHI-squared test , *LACTATES , *STATISTICS , *INTENSIVE care units , *SURVIVAL analysis (Biometry) , *BIOMARKERS - Abstract
Background: Reliable predictors of outcomes in venoarterial extracorporeal membrane oxygenation (VA-ECMO) therapy are limited. While elevated lactate levels over time have been linked to outcomes in cardiogenic shock (CS), their significance in VA-ECMO-treated patients remains inconclusive. Methods: We conducted a post hoc analysis of data from the HYPO-ECMO trial, which compared normothermia to moderate hypothermia in CS patients supported by VA-ECMO. We examined daily lactate levels collected over a week to assess their correlation with 30-day mortality. Results: Among the 318 out of 334 patients (95%) with baseline lactate measurements, 66 had normal levels (< 2.2 mmol/l, 21%). No difference was found in lactate course between moderate hypothermia and normothermia groups. Lactate levels were consistently higher in non-survivors at each time point (p = 0.0002). Baseline hyperlactatemia was associated with an increased risk of death (Hazard Ratio [HR]: 1.85 (1.12–3.05), p = 0.016). When considering all time points, lactate levels during the ICU stay were significantly and gradually associated with a higher risk of death (p < 0.0001). In the overall population, a decrease in lactate levels was not linked to 30-day mortality. However, patients with baseline hyperlactatemia exhibited a more significant decrease in lactate levels from day one to seven (p < 0.0001). In this group, survivors had a significantly greater decrease in lactate levels at day 1 compared to non-survivors (63% (48–77) versus 57% (21–75), p = 0.026). Patients experiencing a secondary increase in lactate (24%) had a worse prognosis (Hazard Ratio: 1.78 (1.21–2.61), p = 0.004), regardless of both baseline lactate levels and the occurrence of severe ischemic adverse events (intestinal and/or limb ischemia). Conclusions: The consistent and significant association between lactate levels, whether assessed at baseline or during ICU treatment, and the risk of mortality underscores the pivotal prognostic relevance of lactate levels in patients with CS undergoing VA-ECMO therapy. The study findings provide some novel insights, regarding the trend profile and the relevance of a second peak during the 7 day period after ECMO start. Trial Registration identifier NCT02754193 registered on 2016–04–12. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
181. Right ventricular injury in patients with COVID-19-related ARDS eligible for ECMO support: a multicenter retrospective study.
- Author
-
Petit, Matthieu, Bouaoud, Misylias, Jullien, Edouard, Joseph, Adrien, Evrard, Bruno, Charron, Cyril, Daulasim, Anousone, Legras, Annick, Gourraud, Maeva, Goudelin, Marine, Vignon, Philippe, and Vieillard-Baron, Antoine
- Subjects
- *
ADULT respiratory distress syndrome , *EXTRACORPOREAL membrane oxygenation , *QUALITATIVE research , *SCIENTIFIC observation , *KRUSKAL-Wallis Test , *FISHER exact test , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *QUANTITATIVE research , *MANN Whitney U Test , *CHI-squared test , *KAPLAN-Meier estimator , *RESEARCH , *INTENSIVE care units , *RIGHT heart ventricle , *SURVIVAL analysis (Biometry) , *CONFIDENCE intervals , *DATA analysis software , *COVID-19 , *DISEASE incidence , *ECHOCARDIOGRAPHY , *PROPORTIONAL hazards models , *DISEASE risk factors - Abstract
Background: Coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) is associated with high mortality. Extracorporeal membrane oxygenation (ECMO) has been proposed in this setting, but optimal criteria to select target patients remain unknown. Our hypothesis is that evaluation of right ventricular (RV) function could be helpful. The aims of our study were to report the incidence and outcomes of patients eligible for ECMO according to EOLIA criteria, and to identify a subgroup of patients with RV injury, which could be a target for ECMO. Methods: Retrospective observational study involving 3 French intensive care units (ICUs) of teaching hospitals. Patients with confirmed SARS-CoV-2 infection between March 2020 and March 2021, presenting ARDS and with available echocardiography, were included. Patients were classified in three groups according to whether or not they met the EOLIA criteria and the presence of RV injury (RVI) ("EOLIA −", "EOLIA + RVI −" and "EOLIA + RVI + "). RVI was defined by the association of RV to left ventricular end-diastolic area ratio > 0.8 and paradoxical septal motion. Kaplan–Meier survival curves were used to analyze outcome as well as a Cox model for 90 day mortality. Results: 915 patients were hospitalized for COVID-19, 418 of them with ARDS. A total of 283 patients with available echocardiography were included. Eighteen (6.3%) patients received ECMO. After exclusion of these patients, 107 (40.5%) were classified as EOLIA −, 126 (47.5%) as EOLIA + RVI −, and 32 (12%) as EOLIA + RVI +. Ninety-day mortality was 21% in the EOLIA-group, 44% in the EOLIA + RVI-group, and 66% in the EOLIA + RVI + group (p < 0.001). After adjustment, RVI was statistically associated with 90-day mortality (HR = 1.92 [1.10–3.37]). Conclusions: Among COVID-19-associated ARDS patients who met the EOLIA criteria, those with significant RV pressure overload had a particularly poor outcome. This subgroup may be a more specific target for ECMO. This represented 12% of our cohort compared to 60% of patients who met the EOLIA criteria only. How the identification of this high-risk subset of patients translates into patient-centered outcomes remains to be evaluated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
182. Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?
- Author
-
Lüsebrink, Enzo, Binzenhöfer, Leonhard, Hering, Daniel, Villegas Sierra, Laura, Schrage, Benedikt, Scherer, Clemens, Speidl, Walter S., Uribarri, Aitor, Sabate, Manel, Noc, Marko, Sandoval, Elena, Erglis, Andrejs, Pappalardo, Federico, deric De Roeck, Fre, Tavazzi, Guido, Riera, Jordi, Roncon-Albuquerque Jr, Roberto, Meder, Benjamin, Luedike, Peter, and Rassaf, Tienush
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *CARDIOGENIC shock , *MYOCARDIAL infarction , *ARTIFICIAL blood circulation , *VENTRICULAR fibrillation , *CARDIAC arrest - Abstract
The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA trial (Prague Out-of-Hospital Cardiac Arrest) provided some evidence in favor of VA-ECMO in the setting of out-of-hospital cardiac arrest, the INCEPTION trial (Early Initiation of Extracorporeal Life Support in Refractory Out-of-Hospital Cardiac Arrest) has not found a relevant improvement of short-term mortality with extracorporeal cardiopulmonary resuscitation. In addition, the results of the recently published ECLS-SHOCK trial (Extracorporeal Life Support in Cardiogenic Shock) and ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) discourage the routine use of VA-ECMO in patients with infarct-related cardiogenic shock. Ongoing clinical trials (ANCHOR [Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock, NCT04184635], REVERSE [Impella CP With VA ECMO for Cardiogenic Shock, NCT03431467], UNLOAD ECMO [Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO, NCT05577195], PIONEER [Hemodynamic Support With ECMO and IABP in Elective Complex High-risk PCI, NCT04045873]) may clarify the usefulness of VA-ECMO in specific patient subpopulations and the efficacy of combined mechanical circulatory support strategies. Pending further data to refine patient selection and management recommendations for VA-ECMO, it remains uncertain whether the present usage of this device improves outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
183. Mortality in patients with normal left ventricular function requiring emergency VA-ECMO for postcardiotomy cardiogenic shock due to coronary malperfusion.
- Author
-
Kang, Jagdip, Marin-Cuartas, Mateo, Flo Forner, Anna, Menon, Priya R., Ginther, André, Saaed, Diyar, de Waha, Suzanne, Meineri, Massimiliano, Ender, Jörg, and Borger, Michael A.
- Subjects
- *
CARDIOGENIC shock , *INTRA-aortic balloon counterpulsation , *CORONARY vasospasm , *ACUTE kidney failure , *EXTRACORPOREAL membrane oxygenation , *PERIPHERAL vascular diseases , *VENTRICULAR ejection fraction , *TRANSCRANIAL magnetic stimulation - Abstract
Objectives: To analyze outcomes in patients with normal preoperative left ventricular ejection fraction (LVEF) undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO) therapy due to postcardiotomy cardiogenic shock (PCCS) related to coronary malperfusion. Methods: Retrospective single-center analysis in patients with normal preoperative LVEF treated with VA-ECMO for coronary malperfusion-related PCCS between May 1998 and May 2018. The primary outcome was 30-day mortality, which was compared using the Kaplan-Meier method and the log-rank test. Multivariable logistic regression was performed to identify predictors of mortality. Results: During the study period, a total of 62,125 patients underwent cardiac surgery at our institution. Amongst them, 59 patients (0.1%) with normal preoperative LVEF required VA-ECMO support due to coronary malperfusion-related PCCS. The mean duration of VA-ECMO support was 6 days (interquartile range 4–7 days). The 30-day mortality was 50.8%. Under VA-ECMO therapy, a complication composite outcome of bleeding, re-exploration for bleeding, acute renal failure, acute liver failure, and sepsis occurred in 51 (86.4%) patients. Independent predictors of 30-day mortality were lactate levels > 9.9 mmol/l before VA-ECMO implantation (odds ratio [OR]: 3.3; 95% confidence interval [CI] 1.5–7.0; p = 0.002), delay until revascularization > 278 minutes (OR: 2.9; 95% CI 1.3–6.4; p = 0.008) and peripheral arterial artery disease (OR: 3.3; 95% 1.6–7.5; p = 0.001). Conclusions: Mortality rates are high in patients with normal preoperative LVEF who develop PCCS due to coronary malperfusion. The early implantation of VA-ECMO before the development of profound tissue hypoxia and early coronary revascularization increases the likelihood of survival. Lactate levels are useful to define optimal timing for the VA-ECMO initiation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
184. Extracorporeal Membrane Oxygenation in Acute Respiratory Failure due to Hemorrhagic Alveolitis in a Patient with Acute Myeloblastic Leukemia.
- Author
-
Cuccarelli, Martina, Schiavoni, Lorenzo, Agrò, Felice Eugenio, Pascarella, Giuseppe, Costa, Fabio, Cataldo, Rita, Carassiti, Massimiliano, and Mattei, Alessia
- Subjects
- *
NONINVASIVE ventilation , *ARTIFICIAL respiration , *ACUTE myeloid leukemia , *ADULT respiratory distress syndrome , *EXTRACORPOREAL membrane oxygenation , *BLOOD platelet transfusion , *POSITIVE end-expiratory pressure , *BLOOD transfusion reaction - Abstract
Introduction. Extracorporeal membrane oxygenation (ECMO) support for severe acute respiratory distress syndrome (ARDS) is nowadays widely used with notable results on the overall survival as reported in the ELSO registry near to 55% at 90 days. This is the reason why ECMO teams force the use of this extreme technique to several populations, even though there is still a lack of data about its use on hematological patients. Case Report. A 39-year-old woman without a history of previous diseases, but a new diagnosis of acute myeloblastic leukemia (AML) was admitted to intensive care unit (ICU) for worsening hypoxia and respiratory acidosis, presenting an ARDS with Pa O 2 / Fi O 2 < 100 in spontaneous breathing treated with noninvasive ventilation via full-face mask. Meanwhile, chemotherapy was started leading to a severe bone marrow aplasia that was managed with multiple blood and platelet transfusions. These conditions did not allow physicians to start any invasive approaches. After 14 days, ARDS worsened whereas bone marrow recovered, making possible the beginning of an invasive mechanical ventilation, with low positive end-expiratory pressure and a low tidal volume. Moreover, an immediate extracorporeal CO2 removal (ECCO2R) therapy was added. Despite these efforts, no improvement was achieved, and that is why venovenous ECMO throughout femoral-jugular cannulation was applied. A full protective lung ventilation by ultralow tidal volumes was guaranteed. After 2 weeks of ECMO, a gradual weaning from ECMO support was started and completed after two days. No ECMO-related complications were registered. In the end, the patient started her weaning from the mechanical ventilation and reached 12 hours of spontaneous ventilation in oxygen therapy. Discussion. ECMO is used as a rescue therapy in patients affected by severe respiratory failure with life-threatening hypoxia and respiratory acidosis nonresponsive to other maneuvers. However, immunosuppression and coagulopathies of hematological malignancies are considered relative contraindications for ECMO, while long-lasting respiratory failure represents another relative contraindication to extracorporeal support. ECMO could be a valid option to improve the survival of hematological patients with severe ARDS and thrombocytopenia, and management could change case by case, even if high incidence of recurrency. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
185. A Survey to Quantify the Number and Structure of Extracorporeal Membrane Oxygenation Retrieval Programs in the United States.
- Author
-
Mihu, Mircea R., Swant, Laura V., Schoaps, Robert S., Johnson, Caroline, and El Banayosy, Aly
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *CATHETERIZATION , *DATABASES , *HOSPITAL patients , *MEDICAL centers - Abstract
(1) Background: Extracorporeal membrane oxygenation (ECMO) represents a potentially lifesaving support for respiratory and/or circulatory failure but its availability is limited to larger medical centers. A well-organized regional ECMO center with remote cannulation and retrieval ability can offer this intervention to patients treated at hospitals without ECMO. Information regarding the number and structure of ECMO retrieval programs in the United States is limited and there are no data regarding the size and structure of existing programs and which physician specialists perform cannulations and provide management. (2) Methods: We created a survey of 12 questions that was sent out to all adult US ECMO programs registered in the ELSO database. The data for the study were collected through an online survey instrument that was developed in Survey Monkey (Monkey Headquarters, Portland, OR). (3) Results: Approximately half of the centers that received the survey responded: 136 out of 274 (49.6%). Sixty-three centers (46%) have an ECMO retrieval program; 58 of these offer both veno-arterial (V-A) and veno-venous (V-V) ECMO, while 5 programs offer V-V ECMO rescue only. Thirty-three (52%) centers perform less than 10 ECMO retrievals per year, and only five (8%) hospitals can perform more than 50 ECMO rescues per year. Cardiothoracic surgeons perform the majority of the ECMO cannulations during retrievals in 30 programs (48%), followed by intensivists in eight (13%) programs and cardiologists in three (5%) centers. (4) Conclusions: Many ECMO centers offer ECMO retrievals; however, only a minority of the programs perform a large number of rescues per year. These cannulations are primarily performed by cardiothoracic surgeons. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
186. Extra-Corporeal Membrane Oxygenation in Pregnancy.
- Author
-
Romenskaya, Tatsiana, Longhitano, Yaroslava, Mahajan, Aman, Savioli, Gabriele, Voza, Antonio, Tesauro, Manfredi, and Zanza, Christian
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *CARDIOGENIC shock , *FETOFETAL transfusion , *PREGNANT women , *ADULT respiratory distress syndrome , *PREGNANCY complications - Abstract
Extracorporeal membrane oxygenation (ECMO) is a cardiac or pulmonary function support system that is used in cases of refractory organ failure in addition to conventional treatment. Currently, Level I evidence is not yet available, which reflects improved outcomes with ECMO in pregnant women, the use in pregnancy should be indicated in selected cases and only in specialized centers. We searched articles in the most important scientific databases from 2009 until 31 December 2023 consulting also the site ClinicalTrials.com to find out about studies that have been recently conducted or are currently ongoing. We matched the combination of the following keywords: "ECMO and pregnancy", "H1N1 and pregnancy", "COVID-19 and pregnancy", "ARDS and pregnancy", "ECMO and pregnancy AND (cardiac arrest)". We selected the following number of articles for each keyword combination: "ECMO and pregnancy" (665 articles); "ECMO and influenza H1N1" (384 articles); "pregnancy and influenza H1N1" (1006 articles); "pregnancy and ARDS" (2930 articles); "ECMO and pregnancy and ARDS and influenza H1N1" (24 articles); and "[ECMO and pregnancy AND (cardiac arrest)]" (74 articles). After careful inspection, only 43 papers fitted our scope. There are two types of ECMO: venous-venous (VV-ECMO) and venous-arterial (VA-ECMO). The first-one is necessary to cope with severe hypoxia: oxygen-depleted blood is taken from the venous circulation, oxygenated, and carbon dioxide removed from the extracorporeal circuit and returned to the same venous system. The VA-ECMO is a type of mechanical assistance to the circulatory system that allows to put the failing organ at rest by ensuring adequate oxygenation and systemic de-oxygenation, avoiding multi-organ failure. The main indications for ECMO support in pregnant women are cardiogenic shock, acute respiratory distress syndrome (ARDS), pulmonary embolism, and eclampsia. There are also fetal indications for ECMO, and they are fetal distress, hypoxic-ischemic encephalopathy (HIE), and twin-to-twin transfusion syndrome (TTTS). Until now, based on the outcomes of the numerous clinical studies conducted, ECMO has been shown to be a successful therapeutic strategy in cases where medical treatment has been unsuccessful. In well-selected pregnant patients, it appears to be safe and associated with a low risk of maternal and fetal complications. The aim of this review is to report the main properties of ECMO (VV and VA) and the indications for its use in pregnant women. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
187. Analysis of Patients with Severe ARDS on VV ECMO Treated with Inhaled NO: A Retrospective Observational Study.
- Author
-
Muenster, Stefan, Nadal, Jennifer, Schewe, Jens-Christian, Ehrentraut, Heidi, Kreyer, Stefan, Putensen, Christian, and Ehrentraut, Stefan Felix
- Subjects
- *
ACUTE kidney failure , *ADULT respiratory distress syndrome , *PULMONARY arterial hypertension , *EXTRACORPOREAL membrane oxygenation , *RENAL replacement therapy - Abstract
(1) Background: This retrospective study focused on severe acute respiratory distress syndrome (ARDS) patients treated with veno-venous (VV) extracorporeal membrane oxygenation (ECMO) and who inhaled nitric oxide (NO) for pulmonary arterial hypertension (PAH) and/or right ventricular failure (RV failure). (2) Methods: Out of 662 ECMO-supported patients, 366 received VV ECMO, including 48 who inhaled NO. We examined the NO's indications, dosing, duration, and the ability to lower PAH. We compared patients with and without inhaled NO in terms of mechanical ventilation duration, ECMO weaning, organ dysfunction, in-hospital mortality, and survival. (3) Results: Patients received 14.5 ± 5.5 ppm NO for 3 days with only one-third experiencing decreased pulmonary arterial pressure. They spent more time on VV ECMO, had a higher ECMO weaning failure frequency, and elevated severity scores (SAPS II and TIPS). A Kaplan–Meier analysis revealed reduced survival in the NO group. Multiple variable logistic regression indicated a twofold increased risk of death for ARDS patients on VV ECMO with NO. We observed no increase in continuous renal replacement therapy. (4) Conclusions: This study suggests that persistent PAH and/or RV failure is associated with poorer outcomes in severe ARDS patients on VV-ECMO, with an inhaled NO responder rate of only 30%, and it does not impact acute kidney failure rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
188. Impact of the Timing of Mechanical Circulatory Support on the Outcomes in Myocardial Infarction-Related Cardiogenic Shock: Subanalysis of the PREPARE CS Registry.
- Author
-
Prunea, Dan M., Bachl, Eva, Herold, Lukas, Kanoun Schnur, Sadeek S., Pätzold, Sascha, Altmanninger-Sock, Siegfried, Sommer, Gudrun A., Glantschnig, Theresa, Kolesnik, Ewald, Wallner, Markus, Ablasser, Klemens, Bugger, Heiko, Buschmann, Eva, Praschk, Andreas, Fruhwald, Friedrich M., Schmidt, Albrecht, von Lewinski, Dirk, and Toth, Gabor G.
- Subjects
- *
ARTIFICIAL blood circulation , *CARDIOGENIC shock , *INTRA-aortic balloon counterpulsation , *EXTRACORPOREAL membrane oxygenation , *IMPACT (Mechanics) , *MYOCARDIAL infarction , *HOSPITAL mortality - Abstract
(1) Background: Mechanical circulatory support (MCS) in myocardial infarction-associated cardiogenic shock is subject to debate. This analysis aims to elucidate the impact of MCS's timing on patient outcomes, based on data from the PREPARE CS registry. (2) Methods: The PREPARE CS prospective registry includes patients who experienced cardiogenic shock (SCAI classes C–E) and were subsequently referred for cardiac catheterization. Our present analysis included a subset of this registry, in whom MCS was used and who underwent coronary intervention due to myocardial infarction. Patients were categorized into an Upfront group and a Procedural group, depending on the timing of MCS's introduction in relation to their PCI. The endpoint was in-hospital mortality. (3) Results: In total, 71 patients were included. MCS was begun prior to PCI in 33 (46%) patients (Upfront), whereas 38 (54%) received MCS during or after the initiation of PCI (Procedural). The groups' baseline characteristics and hemodynamic parameters were comparable. The Upfront group had a higher utilization of the Impella® device compared to extracorporeal membrane oxygenation (67% vs. 33%), while the Procedural group exhibited a balanced use of both (50% vs. 50%). Most patients suffered from multi-vessel disease in both groups (82% vs. 84%, respectively; p = 0.99), and most patients required a complex PCI procedure; the latter was more prevalent in the Upfront group (94% vs. 71%, respectively; p = 0.02). Their rates of complete revascularization were comparable (52% vs. 34%, respectively; p = 0.16). Procedural CPR was significantly more frequent in the Procedural group (45% vs. 79%, p < 0.05); however, in-hospital mortality was similar (61% vs. 79%, respectively; p = 0.12). (4) Conclusions: The upfront implantation of MCS in myocardial infarction-associated CS did not provide an in-hospital survival benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
189. Detection of Acute Brain Injury in Intensive Care Unit Patients on ECMO Support Using Ultra-Low-Field Portable MRI: A Retrospective Analysis Compared to Head CT.
- Author
-
Cho, Sung-Min, Khanduja, Shivalika, Kim, Jiah, Kang, Jin Kook, Briscoe, Jessica, Arlinghaus, Lori R., Dinh, Kha, Kim, Bo Soo, Sair, Haris I., Wandji, Audrey-Carelle N., Moreno, Elena, Torres, Glenda, Gavito-Higuera, Jose, Choi, Huimahn A., Pitts, John, Gusdon, Aaron M., and Whitman, Glenn J.
- Subjects
- *
INTENSIVE care patients , *BRAIN injuries , *INTENSIVE care units , *EXTRACORPOREAL membrane oxygenation , *HEMORRHAGIC stroke - Abstract
Early detection of acute brain injury (ABI) is critical to intensive care unit (ICU) patient management and intervention to decrease major complications. Head CT (HCT) is the standard of care for the assessment of ABI in ICU patients; however, it has limited sensitivity compared to MRI. We retrospectively compared the ability of ultra-low-field portable MR (ULF-pMR) and head HCT, acquired within 24 h of each other, to detect ABI in ICU patients supported on extracorporeal membrane oxygenation (ECMO). A total of 17 adult patients (median age 55 years; 47% male) were included in the analysis. Of the 17 patients assessed, ABI was not observed on either ULF-pMR or HCT in eight patients (47%). ABI was observed in the remaining nine patients with a total of 10 events (8 ischemic, 2 hemorrhagic). Of the eight ischemic events, ULF-pMR observed all eight, while HCT only observed four events. Regarding hemorrhagic stroke, ULF-pMR observed only one of them, while HCT observed both. ULF-pMR outperformed HCT for the detection of ABI, especially ischemic injury, and may offer diagnostic advantages for ICU patients. The lack of sensitivity to hemorrhage may improve with modification of the imaging acquisition program. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
190. Diaphragm thickness modifications and associated factors during VA-ECMO for a cardiogenic shock: a cohort study.
- Author
-
Moury, Pierre-Henri, Béhouche, Alexandre, Bailly, Sébastien, Durand, Zoé, Dessertaine, Géraldine, Pollet, Angelina, Jaber, Samir, Verges, Samuel, and Albaladejo, Pierre
- Subjects
- *
CARDIOGENIC shock , *DIAPHRAGM (Anatomy) , *EXTRACORPOREAL membrane oxygenation , *RESEARCH funding , *SCIENTIFIC observation , *HEART assist devices , *FISHER exact test , *DESCRIPTIVE statistics , *LONGITUDINAL method , *ODDS ratio , *EXTUBATION , *CONFIDENCE intervals , *VENTILATOR weaning , *DATA analysis software , *REGRESSION analysis - Abstract
Background: The incidence, causes and impact of diaphragm thickness evolution in veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock are unknown. Our study investigates its evolution during the first week of VA-ECMO and its relationship with sweep gas flow settings. Methods: We conducted a prospective monocentric observational study in a 12-bed ICU in France, enrolling patients on the day of the VA-ECMO implantation. The diaphragm thickness and the diaphragm thickening fraction (as index of contractile activity, dTF; dTF < 20% defined a low contractile activity) were daily measured for one week using ultrasound. Factors associated with diaphragm thickness evolution (categorized as increased, stable, or atrophic based on > 10% modification from baseline to the last measurement), early extubation role (< day4), and patients outcome at 60 days were investigated. Changes in diaphragm thickness, the primary endpoint, was analysed using a mixed-effect linear model (MLM). Results: Of the 29 included patients, seven (23%) presented diaphragm atrophy, 18 remained stable (60%) and 4 exhibited an increase (17%). None of the 13 early-extubated patients experienced diaphragm atrophy, while 7 (46%) presented a decrease when extubated later (p-value = 0.008). Diaphragm thickness changes were not associated with the dTF (p-value = 0.13) but with sweep gas flow (Beta = − 3; Confidence Interval at 95% (CI) [− 4.8; − 1.2]. p-value = 0.001) and pH (Beta = − 2; CI [− 2.9; − 1]. p-value < 0.001) in MLM. The dTF remained low (< 20%) in 20 patients (69%) at the study's end and was associated with sweep gas flow evolution in MLM (Beta = − 2.8; 95% CI [− 5.2; − 0.5], p-value = 0.017). Odds ratio of death at 60 days in case of diaphragm atrophy by day 7 was 8.50 ([1.4–74], p = 0.029). Conclusion: In our study, diaphragm thickness evolution was frequent and not associated with the diaphragm thickening fraction. Diaphragm was preserved from atrophy in case of early extubation with ongoing VA-ECMO assistance. Metabolic disorders resulting from organ failures and sweep gas flow were linked with diaphragm thickness evolution. Preserved diaphragm thickness in VA-ECMO survivors emphasizes the importance of diaphragm-protective strategies, including meticulous sweep gas flow titration. Key points: Question: How does the diaphragm thickness evolves during the first week of VA-ECMO treatment for a cardiogenic shock and is it associated with sweep gas flow settings? Findings: In patient receiving VA-ECMO for a cardiogenic shock, fewer progressive atrophy was described when early extubation was possible and associated with lower death rate at two months. The diaphragm thickness increased with the sweep gas flow and decreased with the acidosis. Diaphragm thickness evolution did not evolve parallel to the diaphragm thickening fraction. Meaning: In VA-ECMO-treated patients, we advocate for diaphragmatic-protective strategies through the careful titration of sweep gas flows, tight pH control, and the promotion of early extubation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
191. Prognostic effects of cardiopulmonary resuscitation (CPR) start time and the interval between CPR to extracorporeal cardiopulmonary resuscitation (ECPR) on patient outcomes under extracorporeal membrane oxygenation (ECMO): a single-center, retrospective observational study
- Author
-
Vahedian-Azimi, Amir, Hassan, Ibrahim Fawzy, Rahimi-Bashar, Farshid, Elmelliti, Hussam, Salesi, Mahmood, Alqahwachi, Hazim, Albazoon, Fatima, Akbar, Anzila, Shehata, Ahmed Labib, Ibrahim, Abdulsalam Saif, and Ait Hssain, Ali
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *CARDIOPULMONARY resuscitation , *BYSTANDER CPR , *RETURN of spontaneous circulation , *TREATMENT effectiveness , *CARDIAC arrest - Abstract
Background: The impact of the chronological sequence of events, including cardiac arrest (CA), initial cardiopulmonary resuscitation (CPR), return of spontaneous circulation (ROSC), and extracorporeal cardiopulmonary resuscitation (ECPR) implementation, on clinical outcomes in patients with both out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA), is still not clear. The aim of this study was to investigate the prognostic effects of the time interval from collapse to start of CPR (no-flow time, NFT) and the time interval from start of CPR to implementation of ECPR (low-flow time, LFT) on patient outcomes under Extracorporeal Membrane Oxygenation (ECMO). Methods: This single-center, retrospective observational study was conducted on 48 patients with OHCA or IHCA who underwent ECMO at Hamad General Hospital (HGH), the tertiary governmental hospital of Qatar, between February 2016 and March 2020. We investigated the impact of prognostic factors such as NFT and LFT on various clinical outcomes following cardiac arrest, including 24-hour survival, 28-day survival, CPR duration, ECMO length of stay (LOS), ICU LOS, hospital LOS, disability (assessed using the modified Rankin Scale, mRS), and neurological status (evaluated based on the Cerebral Performance Category, CPC) at 28 days after the CA. Results: The results of the adjusted logistic regression analysis showed that a longer NFT was associated with unfavorable clinical outcomes. These outcomes included longer CPR duration (OR: 1.779, 95%CI: 1.218–2.605, P = 0.034) and decreased survival rates for ECMO at 24 h (OR: 0.561, 95%CI: 0.183–0.903, P = 0.009) and 28 days (OR: 0.498, 95%CI: 0.106–0.802, P = 0.011). Additionally, a longer LFT was found to be associated only with a higher probability of prolonged CPR (OR: 1.818, 95%CI: 1.332–3.312, P = 0.006). However, there was no statistically significant connection between either the NFT or the LFT and the improvement of disability or neurologically favorable survival after 28 days of cardiac arrest. Conclusions: Based on our findings, it has been determined that the NFT is a more effective predictor than the LFT in assessing clinical outcomes for patients with OHCA or IHCA who underwent ECMO. This understanding of their distinct predictive abilities enables medical professionals to identify high-risk patients more accurately and customize their interventions accordingly. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
192. Use of bivalirudin after initial heparin management among adult patients on long‐term venovenous extracorporeal support as a bridge to lung transplant: A case series.
- Author
-
Halawi, Hala, Harris, Jesse E., Goodarzi, Ahmad, Yau, Simon, Youssef, Jihad G., Botros, Mena, and Huang, Howard J.
- Subjects
- *
BIVALIRUDIN , *LUNG transplantation , *HEPARIN , *EXTRACORPOREAL membrane oxygenation , *ADULTS - Abstract
A growing body of evidence supports the use of bivalirudin as an alternative to unfractionated heparin (UFH) for the prevention of thrombotic events in patients on venovenous (VV) extracorporeal membrane oxygenation (ECMO). However, data in patients bridged to lung transplantation are limited. In this case series, we describe the outcomes of six patients who were transitioned from UFH to bivalirudin during their course of VV ECMO support as a bridge to lung transplantation. All six patients were on VV ECMO support until transplant, with a median duration of 73 days. Bivalirudin demonstrated a shorter time to first therapeutic activated thromboplastin time (aPTT) level. Additionally, time in therapeutic range was longer while patients were receiving bivalirudin compared to UFH (median 92.9% vs. 74.6%). However, major bleeding and thrombotic events occurred while patients were receiving either anticoagulant. Based on our experience, bivalirudin appears to be a viable option for anticoagulation in VV ECMO patients bridged to lung transplantation. Larger studies evaluating the optimal anticoagulation strategy in patients bridged to transplant are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
193. Ekstrakorporeal Membran Oksijenizasyonunda İlaç ve Doz Optimizasyonu.
- Author
-
Yalçın, Nadir, Akkaya, Mehmet, and Demirkan, Kutay
- Abstract
Extracorporeal membrane oxygenation (ECMO) increases circulating volume of distribution, leading to capillary leakage and temporarily altering renal function. Therefore, this may affect pharmacokinetics. In this review, factors affecting pharmacokinetics and pharmacodynamics in veno-arterial and venovenous ECMO, the causes of drug sequestration that may occur in the ECMO circuit, the effects of physicochemical parameters of drugs in the ECMO circuit, and ECMOvariable dose optimization have been reviewed from the studies in the current literature. Data reported on the limitations, indications and complications of ECMO are also mentioned. The limited use of ECMO in the coronavirus disease-2019 pandemic, its use in reported cases, and which symptoms it is usually used to support the treatment of are described. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
194. Outcomes of Severe ARDS COVID-19 Patients Denied for Venovenous ECMO Support: A Prospective Observational Comparative Study.
- Author
-
Sylvestre, Aude, Forel, Jean-Marie, Textoris, Laura, Gragueb-Chatti, Ines, Daviet, Florence, Salmi, Saida, Adda, Mélanie, Roch, Antoine, Papazian, Laurent, Hraiech, Sami, and Guervilly, Christophe
- Subjects
- *
COVID-19 , *ADULT respiratory distress syndrome , *EXTRACORPOREAL membrane oxygenation - Abstract
Background: Few data are available concerning the outcome of patients denied venovenous extracorporeal membrane oxygenation (VV-ECMO) relative to severe acute respiratory distress syndrome (ARDS) due to COVID-19. Methods: We compared the 90-day survival rate of consecutive adult patients for whom our center was contacted to discuss VV-ECMO indication. Three groups of patients were created: patients for whom VV-ECMO was immediately indicated (ECMO-indicated group), patients for whom VV-ECMO was not indicated at the time of the call (ECMO-not-indicated group), and patients for whom ECMO was definitely contraindicated (ECMO-contraindicated group). Results: In total, 104 patients were referred for VV-ECMO support due to severe COVID-19 ARDS. Among them, 32 patients had immediate VV-ECMO implantation, 28 patients had no VV-ECMO indication, but 1 was assisted thereafter, and 44 patients were denied VV-ECMO for contraindication. Among the 44 patients denied, 30 were denied for advanced age, 24 for excessive prior duration of mechanical ventilation, and 16 for SOFA score >8. The 90-day survival rate was similar for the ECMO-indicated group and the ECMO-not-indicated group at 62.1 and 61.9%, respectively, whereas it was significantly lower (20.5%) for the ECMO-contraindicated group. Conclusions: Despite a low survival rate, 50% of patients were at home 3 months after being denied for VV-ECMO for severe ARDS due to COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
195. The Jena Method: Perfusionist Independent, Standby Wet-Primed Extracorporeal Membrane Oxygenation (ECMO) Circuit for Immediate Catheterization Laboratory and/or Hybrid Operating Room Deployment.
- Author
-
Haertel, Franz, Kaluza, Mirko, Bogoviku, Jurgen, Westphal, Julian, Fritzenwanger, Michael, Pfeifer, Ruediger, Kretzschmar, Daniel, Doenst, Torsten, Moebius-Winkler, Sven, and Schulze, P. Christian
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *OPERATING rooms , *CATHETERIZATION , *OXYGENATORS - Abstract
Background: The timely initiation of extracorporeal membrane oxygenation (ECMO) is crucial for providing life support. However, delays can occur when perfusionists are not readily available. The Jena Method aims to address this issue by offering a wet-primed ECMO system that can be rapidly established without the perfusionist's presence. Methods: The goal was to ensure prompt ECMO initiation while maintaining patient safety. The method focuses on meeting hygienic standards, safe primed storage of the circuit, staff training, and providing clear step-by-step instructions for the ECMO unit. Results: Since implementing the Jena Method in 2015, 306 patients received VA-ECMO treatment. Bacterial tests confirmed the sterility of the primed ECMO circuits during a 14-day period. The functionality of all the components of the primed ECMO circuit after 14 days, especially the pump and oxygenator, were thoroughly checked and no malfunction was found to this day. To train staff for independent ECMO initiation, a step-by-step system involves safely bringing the ECMO unit to the intervention site and establishing all connections. This includes powering up, managing recirculation, de-airing the system, and preparing it for cannula connection. A self-developed picture-based guide assists in this process. New staff members learn from colleagues and receive quarterly training sessions by perfusionists. After ECMO deployment, the perfusionist provides a new primed system for a potential next patient. Conclusions: Establishing a permanently wet-primed on-demand extracorporeal life support circuit without direct perfusionist support is feasible and safe. The Jena Method enables rapid ECMO deployment and has the potential to be adopted in emergency departments as well. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
196. Mechanical Circulatory Support Systems in Fulminant Myocarditis: Recent Advances and Outlook.
- Author
-
Lenz, Max, Krychtiuk, Konstantin A., Zilberszac, Robert, Heinz, Gottfried, Riebandt, Julia, and Speidl, Walter S.
- Subjects
- *
HEART assist devices , *CARDIOGENIC shock , *MYOCARDITIS , *EXTRACORPOREAL membrane oxygenation , *INTENSIVE care units , *HEART transplantation - Abstract
Background: Fulminant myocarditis (FM) constitutes a severe and life-threatening form of acute cardiac injury associated with cardiogenic shock. The condition is characterised by rapidly progressing myocardial inflammation, leading to significant impairment of cardiac function. Due to the acute and severe nature of the disease, affected patients require urgent medical attention to mitigate adverse outcomes. Besides symptom-oriented treatment in specialised intensive care units (ICUs), the necessity for temporary mechanical cardiac support (MCS) may arise. Numerous patients depend on these treatment methods as a bridge to recovery or heart transplantation, while, in certain situations, permanent MCS systems can also be utilised as a long-term treatment option. Methods: This review consolidates the existing evidence concerning the currently available MCS options. Notably, data on venoarterial extracorporeal membrane oxygenation (VA-ECMO), microaxial flow pump, and ventricular assist device (VAD) implantation are highlighted within the landscape of FM. Results: Indications for the use of MCS, strategies for ventricular unloading, and suggested weaning approaches are assessed and systematically reviewed. Conclusions: Besides general recommendations, emphasis is put on the differences in underlying pathomechanisms in FM. Focusing on specific aetiologies, such as lymphocytic-, giant cell-, eosinophilic-, and COVID-19-associated myocarditis, this review delineates the indications and efficacy of MCS strategies in this context. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
197. Drug–Drug Interactions in Patients with Acute Respiratory Distress Syndrome.
- Author
-
Bischof, Thorsten, Schaller, Christoph, Buchtele, Nina, Staudinger, Thomas, Ullrich, Roman, Kraft, Felix, Andersson, Marine L., Jilma, Bernd, and Schoergenhofer, Christian
- Subjects
- *
ADULT respiratory distress syndrome , *DRUG interactions , *COVID-19 , *EXTRACORPOREAL membrane oxygenation , *INTENSIVE care units - Abstract
Acute respiratory distress syndrome (ARDS) is a potential life-threatening, heterogenous, inflammatory lung disease. There are no data available on potential drug–drug interactions (pDDIs) in critically ill patients with ARDS. This study analyzed pDDIs in this specific cohort and aimed to investigate possible associations of coronavirus disease 2019 (COVID-19) as an underlying cause of ARDS and treatment with extracorporeal membrane oxygenation (ECMO) with the occurrence of pDDIs. This retrospective study included patients ≥18 years of age diagnosed with ARDS between January 2010 and September 2021. The Janusmed database was used for the identification of pDDIs. A total of 2694 pDDIs were identified in 189 patients with a median treatment duration of 22 days. These included 323 (12%) clinically relevant drug combinations that are best avoided, corresponding to a median rate of 0.05 per day. There was no difference in the number of pDDIs between COVID-19- and non-COVID-19-associated ARDS. In patients treated with ECMO, the rate of the most severely graded pDDIs per day was significantly higher compared with those who did not require ECMO. PDDIs occur frequently in patients with ARDS. On average, each patient may encounter at least one clinically relevant drug combination that should be avoided during their intensive care unit stay. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
198. New developments in guidelines for brain death/death by neurological criteria.
- Author
-
Greer, David M., Lewis, Ariane, and Kirschen, Matthew P.
- Subjects
- *
BRAIN death , *TRANSCRANIAL Doppler ultrasonography , *NEURAL development , *CEREBRAL circulation , *EXTRACORPOREAL membrane oxygenation - Abstract
The declaration of brain death (BD), or death by neurological criteria (DNC), is medically and legally accepted throughout much of the world. However, inconsistencies in national and international policies have prompted efforts to harmonize practice and central concepts, both between and within countries. The World Brain Death Project was published in 2020, followed by notable revisions to the Canadian and US guidelines in 2023. The mission of these initiatives was to ensure accurate and conservative determination of BD/DNC, as false-positive determinations could have major negative implications for the medical field and the public's trust in our ability to accurately declare death. In this Review, we review the changes that were introduced in the 2023 US BD/DNC guidelines and consider how these guidelines compare with those formulated in Canada and elsewhere in the world. We address controversies in BD/DNC determination, including neuroendocrine function, consent and accommodation of objections, summarize the legal status of BD/DNC internationally and discuss areas for further BD/DNC research. This Review reviews changes introduced into the US brain death/death by neurological criteria (BD/DNC) guidelines in 2023 and compares these guidelines with those formulated elsewhere in the world. The authors highlight controversies and legal challenges in BD/DNC determination and discuss future research priorities. Key points: Brain death (BD), or death by neurological criteria (DNC), has been a medically and legally accepted formulation of death throughout the world for more than half a century. Guideline updates are intended to strengthen the methods and practice of BD/DNC determination; these include the World Brain Death Project (WBDP) in 2020, the Canadian guideline update in 2023, and the US combined paediatric and adult guidelines from multiple societies in 2023. New guidance has emerged for BD/DNC determination in several challenging circumstances, including hypothermia, carbon dioxide retention, primary infratentorial injury, extracorporeal membrane oxygenation and pregnancy. Guidelines continue to emphasize a meticulous and systematic approach, erring on the conservative side, to reduce the possibility of false-positive BD/DNC determination. Acceptable ancillary tests, which are only to be used when a complete clinical evaluation is not possible or safe, comprise tests of cerebral blood flow, such as four-vessel catheter angiography, radionuclide perfusion scintigraphy and transcranial Doppler ultrasonography (in adults only). EEG is no longer accepted as an ancillary test, and the most recent US guidelines and the WBDP do not permit the use of CT angiography. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
199. Backflow at the inlet of centrifugal blood pumps enhanced by geometrical features.
- Author
-
Rorro, Federico, Fiusco, Francesco, Broman, Lars Mikael, and Prahl Wittberg, Lisa
- Subjects
- *
CENTRIFUGAL pumps , *EXTRACORPOREAL membrane oxygenation , *SWIRLING flow , *INLETS , *BLOOD flow - Abstract
Extracorporeal life support (ECLS) includes life-saving support in severe acute cardiac and/or pulmonary failure. In the past 20 years, centrifugal pumps have become the primary choice to deliver the required blood flow. Pumps of various designs, with different approved operating ranges, are today available to clinicians. The use of centrifugal pumps in the low flow condition has been shown to increase hemolytic and thrombogenic risks of the treatment. Further, low flow operation has been associated with retrograde flow at the pump inlet. In this study, experimental and numerical methods have been applied to investigate the operating conditions and fluid dynamical mechanisms leading to reverse flow (or backflow) at the inlet. Reverse flow was predominantly observed in pumps having a top shroud covering the impeller blades, showing a relation between pump geometry and backflow. The shroud divides the pump volume above the impeller into two regions, separating the swirling reverse flow migrating toward the upper pump volute from the main flow, reducing the dissipation of the vortical structures, and allowing the swirling reverse flow to reach further in the pump inlet. At the inlet, backflow was observed as stable recirculation areas at the side of the pump inlet. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
200. Reevaluating Rehabilitation Practice for Patients Who Were Critically Ill After COVID-19 Infection: An Administrative Case Report.
- Author
-
Clancy, Malachy J, Tevald, Michael A, Adler, Joe, Butler, Kelly, Courtwright, Andrew M, Diamond, Joshua M, Crespo, Maria M, and Bermudez, Christian A
- Subjects
- *
PULMONOLOGISTS , *NURSES , *PATIENT selection , *HEMOTHORAX , *RISK assessment , *CRITICALLY ill , *PATIENTS , *HUMAN services programs , *EXTRACORPOREAL membrane oxygenation , *LUNG transplantation , *INTERPROFESSIONAL relations , *ADULT respiratory distress syndrome , *REHABILITATION , *ABDOMINAL surgery , *THERAPEUTIC embolization , *PNEUMOTHORAX , *ALLIED health personnel , *HEART transplantation , *JEJUNOSTOMY , *SURGICAL complications , *ARTIFICIAL respiration , *INTENSIVE care units , *CARDIOVASCULAR surgery , *ELIGIBILITY (Social aspects) , *PHYSICIANS , *PERFUSIONISTS , *CHEST tubes , *COVID-19 , *PULMONARY fibrosis , *CHOLECYSTITIS , *DISEASE risk factors - Abstract
Objective The goal of this case report is to describe the process, challenges, and opportunities of implementing rehabilitation for individuals who were critically ill and required both mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO) support following a coronavirus 2019 (COVID-19) infection in an academic medical center. Methods This administrative case report is set in a heart and vascular intensive care unit, a 35-bed critical care unit that provides services for patients with various complex cardiovascular surgical interventions, including transplantation. Patients were admitted to the heart and vascular intensive care unit with either COVID-19 acute respiratory distress syndrome or pulmonary fibrosis for consideration of bilateral orthotropic lung transplantation. The authors describe the process of establishing rehabilitation criteria for patients who, by previously established guidelines, would be considered too ill to engage in rehabilitation. Results The rehabilitation team, in coordination with an interprofessional team of critical care providers including physicians, respiratory care providers, perfusionists, and registered nurses, collaborated to implement a rehabilitation program for patients with critical COVID-19 being considered for bilateral orthotropic lung transplantation. This was accomplished by (1) reviewing previously published guidelines and practices; (2) developing an interdisciplinary framework for the consideration of rehabilitation treatment; and (3) implementing the framework for patients in our heart and vascular intensive care unit. Conclusion In response to the growing volume of patients admitted with critical COVID-19, the team initiated and developed an interprofessional framework and successfully provided rehabilitation services to patients who were critically ill. While resource-intensive, the process demonstrates that rehabilitation can be implemented on a case-by-case basis for select patients receiving extracorporeal membrane oxygenation and MV, who would previously have been considered too critically ill for rehabilitation services. Impact Rehabilitating patients with end-stage pulmonary disease on extracorporeal membrane oxygenation and MV support is challenging but feasible with appropriate interprofessional collaboration and knowledge sharing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.